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Abstract 
 
Cancer has become a major cause of death in modern society. New cancer cases are estimated to 
increase to 22.2 million by 2030. Many chemotherapeutic drugs, such as irinotecan, target the p53 
pathway in rapidly dividing cells. However, chemotherapeutic drugs possess little discrimination 
between normal and cancer cells since they target DNA replication, a normal physiological 
process. Many studies indicate that cancer and normal cells prefer different glucose metabolic 
pathways. Cancer cells rely mainly on glycolysis while normal cells prefer the oxidative 
phosphorylation (OXPHOS). We hypothesise that manipulating the known metabolic programme 
of cancer cells to follow the OXPHOS pathway experienced by normal cells may alleviate side 
effects experienced by normal cells and accelerate cancer cell death. In order to enhance OXPHOS 
optimal pyruvate levels were used. To investigate the effect of this on normal and cancer cell 
division, cell viability and cytotoxicity was measured in real-time using xCELLigence technology. 
Flow cytometry was then used to determine the mode of cell death and cell cycle changes induced 
by the various treatments. In order to characterise the molecular bases of this, differential gene 
expression upon treatment with the various drugs was measured by RT-PCR and Western blot 
analysis. Furthermore, we conducted microarray analyses using the Human Cancer PathwayFinder 
array to determine pathways affected by the drug combination in A549 lung fibroblast cancer and 
a normal lung fibroblast (MRC-5). Differentially expressed genes with a fold change ≥ 2 were 
analysed by PANTHER, GeneMania and Reactome. Overall, this study shows that the reversal of 
the metabolic program in A549 and MDA-MB 231 cancer cells with chemotherapeutic agents 
accelerates the death of cancer cells while promoting the survival of normal MRC-5 cells.  
However, in the breast cancer cell line, MDA-MB 231 with mutant p53, it is observed that 
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inhibition of proliferation is by another cell death mechanism. RT-PCR and western blot analyses 
indicate that introduction of exogenous methyl pyruvate enhanced the p53/p21 axis of the 
apoptotic pathway resulting in cancer cell death. While promoting survival in MRC-5 normal lung 
fibroblast cells by turning off the p53/p21 axis of the apoptotic pathway. Furthermore, the 
introduction of exogenous methyl pyruvate promotes MRC-5 cell proliferation by modulating the 
expression of RBBP6 isoform 1 and isoform 3. Microarray analysis indicates alterations in specific 
genes promote the survival and growth of MRC-5 normal cells and death of A549 lung cancer 
cells. This knowledge may provide an opportunity to protect patients who undergo chemotherapy 
from the harsh side-effects and increase the success rate of chemotherapeutic drugs. 
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Quotation 
 
 
 
 
 
 
 
 
 
 
 
The future belongs to those who believe in the beauty of their dreams  
 
- Eleanor Roosevelt  
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Chapter 1: Literature Review  
              
 
1. Introduction 
 
Energy metabolism is an important process in cell growth and division. Previous studies have 
indicated, that cancer cells preferentially utilize the glycolysis pathway for energy production 
and to fuel their growth. Otto Warburg first proposed the “Warburg effect” predicting that 
cancer cells even in the presence of oxygen will reprogram their metabolism to follow the 
glycolysis pathway as opposed to normal cells that primarily utilise the oxidative 
phosphorylation (OXPHOS) pathway for glucose metabolism (Warburg, 1956). It has been 
suggested that cancer cells limit their energy production to glycolysis to stimulate the pentose 
phosphate pathway for anabolic processes such as lipid synthesis and de novo nucleic acid 
synthesis, consequently enabling their rapid growth (Deberardinis et al., 2008). The tumour 
suppressor protein 53, p53, has recently been observed to regulate metabolic pathways such as 
glycolysis and OXPHOS by regulating crucial gene products (Bensaad et al., 2006). 
DNA damaging agents, such as irinotecan, initiate cancer cell death in a p53-dependent 
mechanism. However, these chemotherapeutic agents possess non-specificity and affect both 
cancer and normal cells which is responsible for the severe side effects observed in patients 
undergoing chemotherapy. Therefore, novel strategies are required to alleviate the damage 
experienced by normal cells. Recently it was shown that when female fruit flies were exposed 
to irinotecan, reproduction was adversely affected. However, when exposed to irinotecan in 
combination with methyl pyruvate, the flies were protected from these adverse effects and the 
development of embryos improved (Hull and Ntwasa, 2010). In the current investigation, 
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methyl pyruvate supplementation was used to alleviate the side effects of irinotecan on a 
normal cell line while reversing the glycolytic phenotype of cancer cells to induce death.  
In this chapter, worldwide cancer statistics were summarized and cancer development briefly 
described followed by a review of energy metabolism in both cancer and normal cells and the 
role of p53 at crucial check points. Furthermore, the importance of p53 including its 
interactions with MDM2 and RBBP6 is discussed. Lastly, the cytotoxicity and 
pharmacokinetics of chemotherapeutic drugs like irinotecan is reviewed, and the biological 
roles of methyl pyruvate are briefly described.  
1.1 Cancer: A worldwide problem 
 
Cancer is a disease characterised as uncontrolled cell division caused by the accumulation of 
specific genetic and epigenetic changes (Bender et al., 1998). According to the World Health 
Organization (WHO), cancer is the second leading cause of death globally. In 2015, 8.8 million 
deaths were cancer-related, with approximately 70% of deaths occurring in low- and middle-
income countries (WHO, 2017). Cancer initiation and progression is mainly attributed to 
lifestyle choices such as: tobacco smoke, alcohol consumption, unhealthy diet, physical 
inactivity, and cancer related infections. Worldwide, cancer-related deaths were attributed to: 
smoking (21%), alcohol (5%), low fruit and vegetable intake (5%), unsafe sex (3%), 
overweight and obesity (2%), physical inactivity (2%), contaminated injections in health-care 
settings (2%), and urban pollution (1%) (Danaei et al., 2005).  
South Africa is rated as the fourth country with the highest cancer deaths based on 27 different 
types of cancers (Jemal et al., 2011). Amongst men lung, prostate, colorectal, stomach and liver 
cancers were found to be the most prevalent while in women breast, colorectal, lung, cervix 
and stomach cancer were most common. Lung and breast cancers resulted in the highest 
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amounts of deaths in men and women, respectively (Jemal et al., 2011). Due to these poor 
statistics, lung and breast cancers are of interest in this study and are discussed further.  
Lung cancer  
Lung cancer has claimed over 1.6 million lives in 2015 (WHO, 2017). The highest lung cancer 
incidence rates were reported in eastern and southern Europe (45.0 and 49.0 per 100 000), and 
North America (48.5 per 100 000) followed by, Micronesia (46.5 per 100 000), and Polynesia 
and Eastern Asia (45.0 per 100 000), with the lowest rates in sub-Saharan Africa (2.8 per 100 
000) (Jemal et al., 2011). Lung cancer has been observed to be amongst the deadliest type of 
cancer in men since survival rate is very low. A survival rate of less than 5 years were measured 
to be 15% in the United States, Europe 10% followed by 8.9% in developing countries per the 
SEER (Surveillance Epidemiology, and End Results) program (Parkin et al., 2005). The reason 
for low survival rate might be the inability to detect lung cancer at its early stages (Jackson et 
al., 2001). 
Lung cancer can be classified into two major classes; the small cell lung cancer (SCLC) and 
the non-small cell lung cancer (NSCLC) (Hainaut and Pfeifer, 2001). Non-small lung cancer 
accounts for most lung cancer related deaths worldwide (Parkin, 2001). NSCLC can be further 
divided into subtypes; adenocarcinoma (40% of lung cancer cases), squamous cell carcinoma 
(30%), large cell carcinoma (15%), and bronchioloalveolar carcinoma (5%) (Aufman and 
Khalil, 2010).  
Several morphological models have been proposed to explain lung cancer development. For 
the squamous carcinoma, it is thought that normal bronchial epithelium is converted into 
hyperplastic, metaplastic and dysplastic lesions due to certain oncogenic triggering. These 
lesions further develop into carcinoma cells that metastasize in the body (Osada and Takahashi, 
2002).  The primary features of invasive tumours include the disruption of the basement 
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membrane integrity resulting in metastasis. MMP-1 (matrix metalloproteinase-1) 
overexpression has been suggested to be responsible for tumour invasion and metastasis (Zhu 
et al., 2001). The main function of matrix metalloproteinases is to degrade the various 
components of the extracellular matrix and basement membrane (Loffek et al., 2011).  
The causes of lung cancer have been attributed to factors such as: tobacco smoke, genetic 
susceptibility, environmental and workplace carcinogens, and nutrition. According to 
epidemiological evidence, smokers have a 10-fold risk of dying from lung cancer compared to 
non-smokers and in heavy smokers this risk is estimated to increase by 15-25-fold (Carbone, 
1992). In the year 2000, it was estimated that 85% of cancer cases in men were attributed to 
smoking while 47% in women (Parkin, 2001). Tobacco-specific N-nitrosamine and polycyclic 
aromatic hydrocarbons such as benzo (a) pyrene have been found to be the major lung 
carcinogens in smoke (Hazelton et al., 2005).  
Molecular evidence suggests that these carcinogens are initiators of most lung cancers, 
inducing genetic and epigenetic alterations such as: inactivation or mutation of the tumour 
suppressor protein, p53 (Ahrendt et al., 2000), activation of all the dominant oncogenes, K-ras 
oncogene (Jackson et al., 2001), and activation of certain growth factor receptors: EGFR/erbB-
1, HER2/erbB-2, HER3/erbB-3, and HER4/erbB-4 (Cappuzo et al., 2005). p53 mutations have 
been reported in more than half of lung cancer cases, with these more commonly associated 
with smokers than non-smokers (Suzuki et al., 1992). It has been reported that benzo(a)pyrene 
diol epoxide, a potent carcinogen in cigarette smoke, bind preferentially to selected regions of 
the p53 gene. This suggests that formations of benzopyrene adducts correlate with high 
frequency of certain p53 mutations in smoking-associated tumours (Ahrendt et al., 2000). 
Therefore, targeting the p53 pathway during chemotherapy presents a promising avenue for 
lung cancer treatment.   
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Current treatment for advanced stage NSCLC includes a two-drug combination of paclitaxel 
plus carboplatin and vinorelbine plus cisplatin (Kelly et al., 2001). Paclitaxel and vinorelbine 
are reported to have similar cytotoxicity activity, inhibiting mitosis through interaction with 
tubulin (Priyadarshini and Aparajitha, 2012). Cisplatin is the parent compound of carboplatin, 
and are both platinum-based drugs which cause DNA cross-linking with paclitaxel/vinorelbine 
leading to modification of the DNA structure thereby inhibiting DNA synthesis (Ozols et al., 
2003). However, these drugs have been reported to be toxic with a high percentage of patients 
being susceptible to resistance (Kelly et al., 2001). New chemotherapeutic strategies (drugs) to 
protect normal cells from the toxic effects of chemotherapy while inhibiting tumour growth 
remain a necessity. 
Breast Cancer  
Breast cancer is the most common and leading cancer-related deaths amongst women 
worldwide. In 2015, breast cancer accounted for 571 000 deaths worldwide (WHO, 2017).   
The highest incident rates have been reported in North America (99.4 per 100 000) followed 
by Western Europe (84.6 per 100 000), Northern Europe (82.5 per 100 000), and Southern 
Europe (82.4 per 100 000) (Parkin et al., 2005). The lowest incidence rates have been reported 
in Africa (< 30 per 100 000) and Asia (Parkin et al. 2005). According to global statistics, 
survival rates have been modest with 73% in developed countries and 57% in developing 
countries (Parkin et al., 2005). Even though the survival rate of breast cancer cases is high, it 
is still the most commonly diagnosed cancer amongst women globally.   
Major risk factors for predisposition to breast cancer include: nulliparity, long menstrual cycle 
history, oral contraceptives, use of post-menopausal hormone, and giving birth at an advanced 
age. Other risk factors consist of, poor diet, lack of physical activity, and alcohol consumption 
(Hulka and Moorman, 2001; Parkin et al., 2005). In North America and several European 
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countries, breast cancer deaths have decreased over the past 25 years mainly due to early 
detection through mammography, less frequent use of postmenopausal hormone therapy and 
improved treatment regimes.  However, countries in Africa and India had an increase of breast 
cancer deaths, which were attributed to physical inactivity, obesity, and lack of early detection 
technology (Ravdin et al., 2007; Jemal et al., 2010).  
Previous reports suggest that mutations in tumour suppressors (BRCA and p53), oncogenic 
activation and the involvement of reproductive hormones such as the estrogen (ER) and 
progesterone (PR) receptors also attribute to the initiation and progression of breast cancer 
(Miki et al., 1994; Kandioler-Eckersberger et al., 2000; Perou et al., 2000). Several models 
have been proposed to describe the development of breast cancer. First, the “Two-Component 
cancer model” proposed by Lilienfeld and Johnson (1955) predicted that breast cancer develops 
by two distinct pathways. The first pathway results from premenopausal tumours that are linked 
to estrogen receptor negative and the second from postmenopausal cancers linked to estrogen 
receptor positive cancers.  Furthermore, Reis-Filho and Pusztai (2011) predicted through gene-
expression profiling data, that there are two distinct classes, estrogen receptor positive intrinsic 
molecular subtypes (Luminal A and luminal B) and estrogen receptor negative intrinsic 
subtypes (HER2-enriched and basal-like). It has been predicted that the intrinsic molecular 
subtypes can be differentiated by the expression of genes involved in the luminal epithelial 
differentiation (ER and PR genes), proliferation (Ki67 gene), basal differentiation, and the 
human growth factor receptor 2 pathway (HER2 gene) (Perou et al., 2000).   
Mutations in BRCA1 and BRCA2 tumour suppressor genes have been linked to early and late-
onset of breast cancer risk (Miki et al., 1994).  These genes have been shown to differentially 
express hormone receptors. Seventy five percent of BRCA1 mutated breast cancers are 
suggested to be estrogen negative and 25% are estrogen positive while the reverse is observed 
in BRCA2 mutated breast cancers (Karp et al., 1997). Mutations in BRCA1 and BRCA2 have 
B. Monchusi: PhD Thesis  
7 
 
been suggested to only attribute for up to 10% of breast cancer cases in developed countries 
(Parkin et al., 2005).  Genetic alteration of the p53 gene has also been linked to the 
susceptibility to early-onset breast cancer. Studies suggest that heterozygote carriers of the 
mutated form of p53 are at high risk of breast cancer (Miki et al., 1994). In a study of patients 
with advanced breast cancers, there was an observed correlation between the chemotherapy 
response rate and the p53 status of the cells. Induced apoptosis during chemotherapy was 
observed in most tumours with normal p53 (Kandioler-Eckersberger et al., 2000). 
Currently, treatment for advanced breast cancer includes a combination of fluorouracil, 
epirubicin and cyclophosphamide (FEC) known to induce p53-dependent apoptosis (Levin et 
al., 1998). Another compound also known to inhibit breast tumours, is paclitaxel which induces 
apoptosis in a p53 independent manner (Hortobagyi et al., 1997). However, studies have shown 
that most patients do not respond to these cytotoxic treatments (Bergh, 1997; Kandioler-
Eckersberger et al., 2000). SN-38 (irinotecan) (whose homologue is used in this study), has 
also been used in the treatment of breast cancer, albeit with little success rate as most patients 
are resistant to the drug (Imai et al., 2003).  This again strengthens the need to find 
chemotherapy strategies that are effective in inhibiting cancer cell growth.  
 
1.2 Metabolic reprogramming of cancer cells 
 
For glucose metabolism, normal cells prefer OXPHOS whereas cancer cells utilize glycolysis. 
Cancer cells use the glycolytic pathway mainly for anabolic processes such as lipid and nucleic 
acid synthesis to support their rapid growth, rather than for mere ATP production (Warburg, 
1956; Locasale and Cantley, 2010).  
Cancer cells are characterized by high rates of lactate production, biosynthesis of 
macromolecules and lipids, and glycolysis (Puzio-Kuter, 2011). Pyruvate produced through 
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glycolysis under anaerobic conditions can be fermented to lactate by the lactate dehydrogenase 
A, regenerating NAD+ from NADH. Lactate (lactic acid), was previously thought to be toxic 
to cancer cells due to acidification; however, recent studies suggest that the import of lactate 
into the cancer cell microenvironment positively influences their growth and survival 
(Sonveaux et al., 2008).  This can be supported with evidence from Shim et al. (1997) and 
Fantin et al. (2006) suggesting that inhibition of lactate dehydrogenase A (LDH-A) can shut 
down the Warburg effect forcing cancer cells to switch their energy metabolism to oxidative 
phosphorylation. The reprogramming of these cancer cells from glycolysis to OXPHOS is 
speculated to inhibit tumour growth. However, the molecular basis of these findings is not fully 
understood. 
Lactate import and export in some cancer cells has been observed to correlate with the 
deactivation or inactivation of certain chemotherapeutic drugs. The over expression of lactate 
transporters (MCTs: monocarboxylate transporters) controls the import and export of lactate. 
MCT1 and MCT4 transporters have been observed to be the main MCTs playing roles in the 
import and export of lactate respectively (Feron, 2009). High lactate levels have been 
implicated in tumour reoccurrence and metastasis (Walenta et al., 2000). A crucial interaction 
exists between the MCT transporters and the LDH enzymes. In MDA-MB 231 breast cancer 
cells, MCT4 transporter and LDHB (lactate dehydrogenase B) were both overexpressed, 
consequently the lactate taken up by these breast cancer cells are converted back to pyruvate 
to achieve maximum ATP production (Hussien and Brooks, 2011).  
Cancer cells limit their energy production to glycolysis to stimulate the pentose phosphate 
pathway (PPP) and consequently enable growth and proliferation. It has been suggested that 
TIGAR (TP53-induced glycolysis and apoptosis regulator) and HK2 (Hexokinase) – an 
enzyme that catalyses the first step of glycolysis - enhance the supply of intermediates to the 
PPP (Maddocks and Vousden, 2011). The NADPH and ribose-5-phosphate produced in the 
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PPP are linked to the biosynthesis of lipids and nucleic acids (Deberardinis et al., 2008). 
Another enzyme, transketolase (TKTL1) has also been suggested to be involved in the PPP, 
contributing to the survival of cancer cells under stress and starvation (Xu et al., 2009). The 
TKTL1 enzyme cleaves xylulose-5-phosphate, a five-carbon sugar, to glyceraldehyde-3-
phosphate, a three-carbon sugar. This glyceraldehyde-3-phosphate can enter the glycolytic 
pathway to generate ATP and lactate (Coy et al., 2005). The NADPH produced has also been 
suggested to enable cancer cells maintain low levels of reduced forms of glutathione (GSH). 
The GSH produced helps to maintain the redox status of cancer cells thereby protecting them 
against antineoplastic agents (Traverso et al., 2013).  
Strong evidence also suggests, that mutations in tumour suppressors and oncogenes can 
influence glycolysis in cancer cells. For instance, mutations in the DNA binding domain of p53 
is suggested to stop the repression of GLUT1 and GLUT4, leading to an increase in glucose 
uptake (Schwartzenberg-Bar-Yoseph et al., 2004). This high glucose uptake consequently 
leads to high glucose metabolism which increases the rate of ATP production during glycolysis, 
favoring cancer progression (Ganapathy-Kanniappan and Geschwind, 2013).  
Since several studies have stipulated the positive role played by the glycolysis pathway in 
cancer progression, inhibition or circumvention of this pathway might provide an avenue to 
hinder growth. 
1.2.1 Glycolysis and p53  
Glycolysis, also known as the Embden-Meyerhof pathway, is the preferred glucose metabolism 
pathway of cancer cells (Warburg, 1956). Cancer cells mainly prefer glycolysis as opposed to 
OXPHOS as they can easily become hypoxic due to their rapid growth which in turn would 
limit the supply of oxygen (Gogvadze et al., 2009). This pathway involves the oxidation of 
glucose to pyruvate with the production of ATP and NADH (Figure 1) (Pelicano et al., 2006).  
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Net reaction: Glucose + 2 NAD+ + Pi  + 2 ADP = 2 Pyruvate + 2 ATP + 2 NADH 
 
The pyruvate produced in the presence of oxygen is oxidized to carbon dioxide and water in 
the TCA cycle, while in the absence of oxygen is fermented to lactate or ethanol. Some normal 
tissues such as the myocardium and brain have been reported to have glycolytic phenotypes in 
the presence of oxygen (Amoedo et al., 2013).  
The p53 protein has been suggested to play an important role in glucose metabolism and its 
presence in a cell, promotes oxidative phosphorylation (OXPHOS) while limiting the 
glycolytic flux by acting on key enzymes (Figure 1) (Bensaad et al., 2006).  Mutations in p53 
have been implicated in most tumours (Miyashita and Reed, 1995).  p53 can limit glucose 
uptake either through the direct suppression of the glucose transporters (GLUT1 and GLUT4), 
or indirectly by the inhibition of NF-κB pathway. (Schwartzenberg-Bar-Yoseph et al., 2004; 
Kawauchi et al., 2008).  
Furthermore, p53 decreases the expression of phosphoglycerate dismutase (PGM). PGM is a 
functional enzyme in the glycolytic pathway that converts 3-phosphoglycerate to 2-
phosphoglycerate- the second intermediate before the formation of the pyruvate isoform 
(Kondoh et al., 2005).  Also, TIGAR gene transcription is shown to be induced by p53 and its 
presence inhibits phosphofructokinase 1 (PFK1) which further impedes glycolysis (Bensaad et 
al., 2006).  The decrease in glycolysis allows entry into the PPP, while limiting oxidative stress-
induced cell death. These observations show that an increased in p53 expression might shunt 
glycolysis to anabolic processes in the PPP.  
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Figure 1: A modified diagram of energy metabolism regulated by p53. p53 modulate the balance 
between glycolysis and oxidative phosphorylation (Pelicano et al., 2006; Maddocks and Vousden, 
2011). When p53 is present, it inhibits IKK which is needed for the activation of GLUT3 thereby 
reducing glucose uptake. p53 can also reduce glucose uptake suppressing the expression of the GLUT1 
and GLUT4 transporters. Glucolysis is further suppressed by p53, by decreasing the expression of 
phosphoglycerate dismutase (PGM) while inducing the expression of TP53-inducible glycolysis and 
apoptosis regulator (TIGAR) which inhibits the PFK1. p53 plays a role in the activation of SCO2 which 
results in the maintenance of the oxidative phosphorylation pathway. The enzymes PDH: represent 
pyruvate dehydrogenase, PK: pyruvate kinase, HK: hexokinase, PGI: phosphoglucose isomerase, and 
GLAPH: GLAP hydrogenase. The dotted lines/arrows were used to present a reaction step that was 
omitted.  
 
1.2.2 Oxidative phosphorylation and p53  
Studies have shown that normal mammalian cells, in the presence of oxygen, prefer the 
oxidative phosphorylation pathway as it is efficient and generates more ATP per glucose 
molecule than glycolysis (Warburg, 1956). The two pyruvate molecules produced from 
glycolysis are each converted to acetyl CoA before entering the TCA cycle (citric acid cycle) 
to produce ATP through oxidative phosphorylation, also known as the electron transport chain 
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(Figure 1). The initial process of oxidative phosphorylation begins with the products of the 
TCA cycle, NADH and FADH, being broken down to produce electron acceptors (H+) 
catalyzed by the enzyme, ATP synthase (complex V). ATP synthase enables the production of 
ATP with the addition of a phosphate group to ADP through a concentration gradient on the 
inner membrane of the mitochondria. Oxidative phosphorylation yields a net reaction of 36 
ATP molecules per glucose molecule (Pelicano et al., 2006).  
p53 increases the expression of synthesis of cytochrome c oxidase 2 (SCO2). SCO2 is an 
important positive regulator of complex IV (cytochrome c oxidase) and AIF (apoptosis 
inducing factor protein) which in turn promotes OXPHOS (Matoba et al., 2006). p53 can also 
promote OXPHOS by upregulating glutaminase 2 (GLS2) which converts glutamine to 
glutamate improving the rate of the TCA cycle. Furthermore, several anti-apoptotic genes have 
been shown to promote OXPHOS. BCL-XL and PUMA, together with p53 influence the outer 
mitochondrial membrane permeabilization ensuring a balance between cell survival and 
apoptosis (Mihara et al., 2003). Understanding the link between p53 and metabolism in both 
normal and cancer cells might aid in establishing better chemotherapy strategies for the 
treatment of cancer.  
 
1.2.3 Glycolytic phenotype of cancer cells: A potential target for therapy  
Many reports over the years have described strategies for achieving therapeutic selectivity 
during chemotherapy. Only recently have metabolic pathways been suggested to be good 
targets (Hanahan and Weinberg, 2011). Warburg initially proposed that cancer cells even in 
the presence of oxygen will prefer the glycolysis pathway while most normal cells the 
OXPHOS pathway for glucose metabolism (Warburg, 1956). A recent study using clinical 
imaging of primary and metastatic cancers with fluoro-deoxy-D-glucose Positron Emission 
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Tomography (Fdg PET) has demonstrated that an increased glucose flux is a common trait of 
human malignancies compared to normal tissues (Gambhir, 2002).  
Currently, several drugs have been documented that are under development or in clinical trials, 
and target the glycolytic metabolism of tumours (Porporato et al., 2011). Some of these drugs 
include; 2-Deoxyglucose (2-DG) a competitor with glucose, which is in phase II clinical trials 
(Gambhir, 2002; Tennant et al., 2010). 3-bromopyruvate, an alkylating agent, has been 
proposed to react with cysteine residues in proteins undergoing preclinical trials (Ko et al., 
2001; Qin et al., 2010). Lonidamine a specific inhibitor of mitochondrial bound hexokinase is 
in clinical trials (Floridi et al., 1981). 3-Pyridyl-1-(4-pyrydinyl)-2-propen-1-one (3PO) is also 
still in preclinical trails, and has been shown to decrease concentration of phosphofructokinase 
2 leading to glucose uptake (Clem et al., 2008). Dichloroacetate (DCA)   inhibits pyruvate 
dehydrogenase kinase (PDK) thereby allowing the entry of pyruvate into the TCA cycle is in 
phase I (brain cancer) and phase II (non-small cell lung cancer) clinical trials (Whitehouseand 
Randle, 1973). 3-Dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxylic 
(FXII), a known malarial LDH (lactate dehydrogenase) inhibitor, was shown to be a 
competitive inhibitor of lactate dehydrogenase 5 (LDH5) in human lymphoma and pancreatic 
cancer xenografts is in preclinical trials (Yu et al., 2001).  Despite their success rate thus far, 
some of these drugs/molecules need to be administered as adjunctives to therapy to maximise 
effectiveness of the primary, main or initial therapy. In a study, 2-deoxyglucose was shown to 
be effective in sensitizing osteosarcoma and non-small cell lung cancer to adriamycin (inhibits 
progression topoisomerase II) and paclitaxel (stabilises the microtubule polymer) (Maschek et 
al., 2004).  
The role of glycolysis in enhancing tumour growth reinforces the need to search for small 
molecules, to bypass or inhibit the glycolytic pathway in cancer cells while increasing the 
effectiveness of chemotherapy drugs.  
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1.3 Cell cycle division and check points  
 
The principle task of the cell cycle is to replicate DNA without errors ensuring that the 
duplicated chromosomal DNA is equally split between two daughter cells (Nigg, 1996). The 
somatic cell cycle can be divided into four distinct phases: the G0/G1 phase, S-phase, G2 phase 
and the M-phase (Figure 2). During the S-phase, DNA is replicated through a process known 
as DNA synthesis which results to two chromatids in each chromosome. The M-phase consists 
of nuclear division, followed by cell division. The G1 and G2 phases are considered as gap 
periods during which the cells prepare themselves for the successful completion of the S and 
M phases. Cells can however exit the cycle- caused by specific anti-mitogenic signals or the 
absence of mitogenic signaling- and enter a non-dividing state (quiescent state) known as the 
G0 phase/ resting phase (Park and Lee, 2003).  
For a successful cell division to occur, checkpoints must be tightly regulated (Park and Lee, 
2003). The cell cycle is controlled by a group of proteins known as the cyclin dependent kinases 
(CDKs) (Sherr, 2000).  The activities of the CDKs are positively regulated by cyclins and by 
the CDK activating kinase (CAK)- a serine/threonine kinase (Nigg, 1996). During the early G1 
phase, the D-type cyclins (D1, D2, and D3) are predicted to interact with two catalytic partners 
(CDK4 and CDK6). As transition occurs from G1 to S phase, the CDK2 forms a complex with 
cyclin E and A. For mitosis to proceed, the CDK1 must form a complex with cyclin A and 
cyclin B (Park and Lee, 2003).  
When damaged DNA is encountered at any point during the cell cycle checkpoints, the 
regulatory signals induce the cyclin dependent kinase inhibitors (CKIs) which act as brakes to 
stop cell cycle progression until damage is fixed (Sherr, 2000). Members of the retinoblastoma 
family; pRB, p107, and p130, are observed to be part of the CKIs and therefore play a crucial 
role in G1 progression. Furthermore, p53 restricts cellular growth by inducing p53-dependent 
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cell cycle arrest, at the G1  and G2 /M checkpoint ensuring damaged DNA does not replicate 
(Adams, 2001; Haupt et al., 2003).  
 
 
Figure 2: Modified Schematic representation of the mammalian cell cycle with the CDK 
regulators and cyclin dependent kinase inhibitors at each phase. Adapted from (Collins et al., 
1997). Progression through the cell cycle phases are controlled by the action of specific CDKs and their 
cyclin subunits. The activity of CDKs is suppressed by two main classes of inhibitory proteins; the 
INK4 family which inhibits the activity of CDK4 and CDK6 and the CIP/KIP family which inhibits the 
activity of CDK2. The abundance of these positive and negative regulators determines the rate of cell 
cycle progression.  
 
1.3.1 Cell cycle changes and development of cancer 
 
The cell cycle process is known to be disrupted in many cancers. Normal healthy cells only 
enter the cell cycle when stimulated by growth signals, which ensures a balance in cell number 
and maintenance of tissue function (Hanahan and Weinberg, 2011). Cancer cells, compared to 
normal cells, have been associated with certain characteristics such as loss of differentiation, 
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limitless replicative potential, self-sufficiency in growth signals, and increased invasiveness 
(Hanahan and Weinberg, 2000).  
Tumour suppressor protein- p53, and gene product- p16, have been suggested to regulate the 
cell cycle (Jacks and Weinberg, 1998). When p53 is mutated it is unable to bind to damaged 
DNA, which further affects the expression of p21.  p21 is a downstream effector gene in the 
p53-pathway and causes cell cycle arrest when induced (Sherr, 2000).  
Moreover, several components of the ERK and PI3K signaling pathways has also been 
implicated in carcinogenesis (Vivanco and Sawyers, 2002; Downward, 2003; Massague, 
2004). Activation of PI3K/Akt signaling along with ERK signaling are known to regulate 
growth factor-stimulated cell cycle progression from G0 /G1 to S-phase (Torii et al., 2006).  It 
has been shown that cyclin D1 expression is enhanced in 50% of breast cancers (Yu et al., 
2001). Activation of ERK signaling pathway has been suggested to  induce first class G1 
cyclins, such as cyclin D which in turn lead to the upregulation of cyclin D – CDK 4/6 complex 
(Lavoie et al., 1996). The activation of the cyclin D- CDK 4/6 kinase activity further leads to 
the subsequent phosphorylation and inactivation of retinoblastoma (Rb), resulting in the 
activation of E2F family of transcription factors. E2F is known to induce the expression of 
various cell cycle genes, including a second class G1 cyclins, such as cyclin E, thereby leading 
to the synthesis of proteins required for S phase entry (Dyson, 1998). Moreover, Human EGF 
receptor-2 (HER2) and Platelet-derived growth factor (PDGF) expression has also been found 
to be elevated in breast cancers and glioblastoma (Vivanco and Sawyers, 2002; Massague, 
2004).  
Furthermore, PI3K/Akt has also been implicated in CDK activation. Through the 
phosphorylation and inhibition of glycogen synthase kinase 3 β (GSK 3 – β), which is known 
to phosphorylate and destabilize cyclin D1 protein, and  the inhibition of FOXO transcription 
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factors known to repress cyclin D 1 expression, inducing expression of p27 (kip1) and p21 
(WAF) (inhibitiors of cyclin activity) (Vivanco and Sawyers, 2002; Wynmann and Marone, 
2005).  Also, it is been found that PTEN, which acts as a PI3K signaling inhibitor is depleted 
in approximately 30 – 40% of all human cancers (Yu et al., 2001).  
 
1.4 Molecular basis of apoptosis 
 
Programmed cell death, also known as apoptosis, is an evolutionary cell death mechanism 
found throughout all species (Wyllie, 1981). DNA damage is one of the internal signals that 
influence the activation of apoptosis (Elledge, 1996). Ataxia telangiectasia mutated (ATM) and 
CHK2 are known as important gatekeeper molecules in response to DNA damage. p53 has 
been established to be a key regulator of DNA damage induced programmed cell death. p53, 
upon DNA damage, become phosphorylated by ATM thereby increasing its stability and 
binding specificity to induce programme cell death (Lukas et al., 2004; Yang et al., 2004). 
Thes failure of this to occur is linked to loss of genomic material and carcinogenesis 
(Hoeijmakers, 2001).  
Apoptosis has been characterised by morphological changes that include membrane blebbing, 
cell shrinking, condensation of nucleoplasm and cytoplasm, cleavage of chromosomal DNA, 
and fragmentation of the nucleus  followed by eventual cell death (Wyllie, 1981). The apoptotic 
machinery is composed of two major pathways: the extrinsic death receptor pathway and the 
intrinsic mitochondrial pathway.  
1.4.1 The extrinsic pathway 
The extrinsic pathway is activated through the binding of the Fas ligand found on the surface 
of a cytotoxic lymphocyte to the Fas death receptor, thereby initiating apoptosis (Wu et al., 
1997). These death receptors (Fas/CD95, PERP, DR4 and DR5/TRAIL) belong to the tumour 
necrosis factor receptor (TNFR) gene family (Nagata and Golstein, 1995). When activated by 
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p53, the death receptors transmit apoptotic signals to the cytoplasmic region of Fas after their 
interactions with specific ligands (Gewies, 2003). This cytoplasmic region of the death receptor 
(Fas) recruits procaspase-8 via the Fas associated death domain (FADD) (Figure 3). FADDs 
are adaptor molecules that contain the death domain allowing them to be recruited to similar 
domains on the activated death receptors (Fas). The interaction between Fas, FADD, and 
procaspase-8 forms the death inducing signal complex (DISC) which further results in the 
activation and the release of caspase-8 (Nagata and Golstein, 1995). Caspase-8 leads to the 
activation of the downstream effector caspases such as procaspase-3 whose activated form, 
caspase-3, is known to execute programmed cell death (Gewies, 2003).  
 
1.4.2 BID: Linking the extrinsic and intrinsic pathways  
BID is an important pro-apoptotic protein as it links the extrinsic and intrinsic pathways 
(Gewies, 2003). Upon DNA damage, the cytoplasmic inactive BID is cleaved by caspase-8 
into the truncated BID (t-BID) which translocates to the mitochondria where it enters the 
mitochondrial membrane and activates Bax. t-BID (BH3-domain containing protein) and BAX 
– proapoptotic protein - are then recruited to the outer membrane of the mitochondria to initiate 
the intrinsic cell death pathway (Haupt et al., 2003) (Figure 3). 
1.4.3 The intrinsic pathway 
The intrinsic mitochondrial cell death pathway is activated by intracellular stress signals such 
as damaged DNA. This pathway involves the release of cytochrome c from the mitochondria 
after its permeabilisation by the Bcl-2 family of proteins. Apoptosis is achieved when 
procaspase-9, the initiator caspase, is cleaved to caspase-9 which in turn activates other effector 
caspases downstream (Gewies, 2003).  
The interaction of the proapoptotic proteins and BH3-domain containing proteins with p53 
induces mitochondrial outer membrane permeabilization (MOMP) (Dewson and Kluck, 2009). 
B. Monchusi: PhD Thesis  
19 
 
MOMP leads to the release of cytochrome c from the mitochondrial intermembrane space into 
the cytosol. Once cytochrome c is released, it binds to Apaf-1 (an adaptor protein), dATP and 
procaspase-9 leading to the activation of caspase-9. Caspase-9 then activates other effector 
caspases (Caspase-3, -6 and -7) resulting in programmed cell death (Crompton, 2000). During 
this process, p53 can also upregulate PUMA and NOXA.  These two proteins bind to anti-
apoptotic proteins (Like the Bcl-2 family protein) thereby preventing their binding to Bax 
which will inhibit outer mitochondrial membrane permeabilization (Chipuk et al., 2004).  
 
Figure 3: A schematic representation of p53-mediated apoptosis in both the extrinsic and intrinsic 
pathways. Adapted from Haupt et al. (2003). p53 is an important regulator for both the intrinsic and 
the extrinsic pathway. p53 upregulates the expression of the BH3-only proteins, PUMA and Noxa which 
further promotes outer mitochondrial membrane permeabilization during intrinsic apoptosis. For the 
extrinsic receptor-mediated pathway to be activated, p53 needs to activate the Fas death receptor found 
on the cell surface of a cytotoxic lymphocyte. 
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1.4.4 Other cell death mechanisms: Necrotic cell death  
Under cellular stress, such as nutrient deficiency, an autophagic program is activated. This 
initiates the breakdown of cellular organelles such as ribosomes and mitochondria which are 
recycled and used for the biosynthesis of macromolecules (such as lipids, nucleic acid and 
proteins). This program is exploited by many cancers (Levine and Kroemer, 2008; Mizushima, 
2007).  
Necrosis, unlike occurs when damaged or inflamed cells become bloated and burst. Necrotic 
cell death has for many years been thought to occur in an upregulated fashion, however, 
emerging research suggests that it is controlled by certain genes thus, a form of programmed 
cell death (necroptosis) (Barkla and Gibson, 1999; Galluzzi and Kroemer, 2008; Roach and 
Clarke, 2000; Zong and Thompson, 2006). 
It has been observed that programmed necrosis occurs due to an increase in mitochondrial-
derived ROS and calcium (Festjens et al., 2006). Increased calcium levels over time have been 
suggested to disrupt mitochondrial inner membrane integrity and thereby reducing the ability 
to generate ATP (Griffiths and Halestrap, 1995) further leading to necrotic cell death.  Necrotic 
cell death can be characterized by morphological changes including, swelling of cell 
membranes, chromatin condensation, and an irregular DNA degradation pattern leading to 
breakdown of plasma membrane thereby releasing the cytoplasmic content into the 
extracellular environment. Also, necrosis triggers inflammatory and autoimmune reactions due 
to the cellular damage that affects neighboring cells caused by the leakage of intracellular 
contents (Escobar et al., 2015).  
The proposed mechanism of necroptosis is suggested to involve the TNF-R, Fas, and TRAIL 
death receptors belonging to the tumour necrosis factor superfamily known to initiate extrinsic 
apoptotic cell death. When procaspase-8 levels are low a different complex is formed, 
involving the activation of TNFR1 leading to the recruitment of TRADD, TRAF and RIPK1 
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which activate Nf-kappaB, JNK, and p38 MAPKs, thereby causing increased ROS and calcium 
production and decreased ATP, leading to necroptosis (Kaczmarek et al., 2013). The 
necroptosis process is RIPK1-dependent in contrast to the apoptotic pathway that is caspase-
dependent.  
1.4.5 Mechanism of apoptosis in cancer cells  
During carcinogenesis, apoptosis is achieved through three distinct mechanisms; impaired 
balance between anti-apoptotic and pro-apoptotic proteins, disruption of death receptors 
signaling, and finally through loss of caspase activity (Daniel and Korsmeyer, 2004; Wong, 
2011 ).   
 
The Bcl-2 family proteins are essential in controlling the intrinsic mitochondrial cell death 
pathway. To date, 20 members of this family have been identified in humans including anti-
apoptotic proteins (Bcl-2, Bcl-XL, Mcl-l, Bfl-1, Bcl-W, Bcl-G) and pro-apoptotic proteins (Bax, 
Bak, Bok, Bad, Bid, Bik, Bim, Bcl-Xs, Krk, Mtd, Nip3, Nix, Noxa, Bcl-B) (Antonsson and 
Martinou, 2000; Oda et al., 2000). For apoptosis to be induced, pro-apoptotic proteins 
translocate and enter the mitochondrial membrane leading to permeabilization of the inner 
and/or outer mitochondrial membrane and the subsequent release of cytochrome c (Antonsson 
and Martinou, 2000). Furthermore, anti-apoptotic proteins such as Bcl-XL are suggested to bind 
and inactivate Apaf-1 which further blocks the activation of caspase-9. However, pro-apoptotic 
proteins when active can displace Bcl-XL from Apaf-1, allowing the activation of caspase-9 
(Green and Reed, 1998). Therefore, cell death or survival is determined by the ratio of 
expression of the pro-apoptotic proteins such as Bax and the anti-apoptotic Bcl-2 or Bcl-XL 
proteins (Kluck et al., 1997).  
It has been found that an overexpression of Bcl-2 promotes cell survival by blocking 
programmed cell death (Hockenbery et al., 1990). Another study showed that Bcl-2 
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overexpression promoted lymphoproliferation and accelerated c-myc-induced 
lymphomagenesis in transgenic mice (Strasser et al., 1990). Moreover, Bcl-XL, a known potent 
death suppressor is upregulated in some tumour types (Reed, 1998). The Bcl family proteins 
have therefore become attractive anti-cancer targets as downregulation of Bcl-2 and Bcl-XL 
has been predicted to restore sensitivity to chemotherapy (Daniel et al., 2001). Current 
anticancer agents targeting the Bcl-2 family include, taxanes, which induce phosphorylation 
and inactivation of Bcl-2 (Haldar et al., 1995). In some studies, resistance to chemotherapy has 
been found to be related to increased levels of expression of Bcl-2 and Bcl-XL (Minn et al., 
1995).  
 
Furthermore, several upstream and downstream components of the p53 pathway such as MDM-
2, ARF, and Bax are known to be mutated in some human tumours (Wallace-Brodeur and 
Lowe, 1999). p53 is a direct transcriptional activator of Bax, a death promoter. Bax expression 
is induced through the binding of p53 to its typical recognition elements located in the Bax 
gene promoter, leading to its direct transactivation following damage DNA signals (Miyashita 
and Reed, 1995).  Bax has been shown to be inactive in certain types of colon cancer and in 
hematopoietic malignancies (Rampino et al., 1997; Meijierink et al., 1998). It has been 
suggested that the mutational inactivation of the proapoptotic genes, Bax or Bak are responsible 
for the resistance to chemotherapy-induced apoptosis in cancer cells (Zhang and Fang, 2005).  
 
Furthermore, glycolytic enzymes, hexokinase-I and hexokinase-II have been found to be 
upregulated in most tumours, including brain tumours (Mathupala et al., 2006). Hexokinase 
enzyme is known to phosphorylate glucose that enters the cell to glucose-6-phosphate. The 
interaction of hexokinase with voltage-dependent anion selective channel (VDAC) permits it 
to use exclusively intra-mitochondrial ATP to phosphorylate glucose, thereby promoting a high 
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rate of glycolysis (Mathupala et al., 2006). VDAC, a protein located in the outer mitochondrial 
membrane is responsible for most of the metabolite fluxes between the cytosol and 
mitochondria (Colombini, 1983). This interaction keeps VDAC in an open state and has further 
been suggested to block binding sites for pro-apoptotic proteins (tBID, Bax) on the outer 
mitochondrial membrane which further prevents induction of apoptosis (Pastorino et al., 2002).   
 
Alterations in TRAIL-mediated death pathways has been reported in many human tumours 
(Beltinger et al., 1998).  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a 
known TNF-related protein that upon binding to its receptors, DR4 or DR5, initiates apoptosis 
through the extrinsic pathway or through necroptosis. TRAIL has become a very attractive 
target for its strong anticancer activity in a wide range of cancer cell types, with minimal 
cytotoxicity to most normal cells (Pitti et al., 1996). It has been suggested that the expression 
of the “decoy” receptors has made normal cells less susceptible to TRAIL-induced apoptosis. 
These “decoy” receptors compete with the DR4 and DR5 receptors for TRAIL, however, do 
not transmit death signals (Pan et al., 1997). TRAIL therapy has been successful in many cancer 
types, however, many cancer cells have been found to be resistant to TRAIL, including 
pancreatic cancer, melanoma, and neuroblastoma (Hinz et al., 2000; Eggert et al., 2001; Fulda 
et al., 2001). To overcome these resistance, combination therapy with TRAIL and 
chemotherapy or radiotherapy has been employed, however this has raised concerns about the 
toxic effect on normal cells or tissues (Shankar and Srivastava, 2004).   
 
Finally, the mammalian inhibitor of apoptosis protein (IAP) family proteins including survivin, 
ML-IAP and livin are possible targets as they are overexpressed in many cancers but not in 
normal adult tissues (Fesik, 2000; Vucic et al., 2000; Kasof and Gomes, 2001).  It has been 
found that elevated levels of survivin are associated with poor prognosis in children with 
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neuroblastoma (Adida et al., 1998).  IAPs are a family of endogenous direct inhibitors of cell-
death caspases (cysteine-aspartyl proteases) conserved throughout animal evolution with 
homologies in viruses, yeast, Drosophila, C.elegans, mice and humans (Deveraux et al., 1997; 
Deveraux and Reed, 1999). The mammalian IAPs include; X-IAP, cIAP-1, cIAP-2, ML-IAP, 
livin and survivin that inhibit active caspase-3, caspase-7, and the activation of caspase-9 (Los 
et al., 1999). Although the mechanisms by which caspase activity is inhibited are not fully 
understood, it has been suggested that the baculovirus IAP repeat (BIR) domains present in all 
IAPs may be involved in the inhibition of caspase activity (Uren et al., 1998).  
 
1.5 p53 structure, function and regulation 
 
The p53 protein was first discovered in 1979 and was thought only to be a cellular partner of 
an oncoprotein (40 large T-antigen) of the simian virus. Only after a few decades was the role 
of p53 as a tumour suppressor uncovered (Levine and Oren, 2009). Human p53 protein is 
encoded as a single copy gene with a molecular weight of 53 kDa. The structure of human p53 
consists of an amino-terminal transactivation domain (TAD) (residue 20-60), a poly-proline 
region (PP) (residue 63-97), an evolutionarily conserved DNA-binding domain (residue 100-
300), a linker region (residue 301-323), a tetramerization domain (TET) (residue 324-355) and 
an unstructured domain located in the carboxy-terminus (CTD) (residue 360-393) (Figure 4) 
(Bekerman and Prives, 2010). Based on sequence and mutagenesis analysis, three nuclear 
localization signals (NLS): NLSI, NLSII, and NLSIII were originally identified in the C 
terminus of p53 (Shaulsky et al., 1990). The sequence from Lysine 305 and arginine 306 to 
NLSI has been suggested to be most active in directing p53 nuclear import, with strong binding 
affinity to importin - alpha (Liang and Clarke, 1989). Furthermore, two nuclear export signals 
(NESs) mediate p53 nuclear export, one located in the C-terminus between residues 340-351 
and another located at the N-terminus between residues 11 and 27 (Stommel et al., 1998; Zhang 
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and Xiong, 2001). It is suggested that the nuclear export of p53 by leucine-rich NES is mediated 
by exportin 1 (Kudo et al., 1998).   
 
 
 
Figure 4: Modified schematic representation of the human p53 domain structure. p53 consists of 
a transactivation subdomain (TAD), a proline rich region (PRP), an evolutionarily conserved DNA-
binding domain, a tetramerization domain (TET) and an unstructured domain located in the carboxy-
terminus (CTD). Adapted from Beckerman and Prives (2010). 
 
p53 is an essential protein, when activated it initiates cell cycle arrest in response to damaged 
DNA through transcriptional activation of downstream effector genes such as p21 (Sherr, 
2000). p53 is speculated to regulate the cell cycle as it accumulates in the cytoplasm during the 
G1 phase and only enters the nucleus during the G1/S phase, then cycles back to the cytoplasm 
(Middeler et al., 1997). In response to DNA damage, p53 can trigger apoptosis via the 
recruitment of the BCL-XL and BH3-domain containing proteins via the intrinsic cell death 
pathway or by activating certain external death receptors (Fas ligand) during the extrinsic cell 
death pathway (Haupt et al., 2003; Wu et al., 1997).  
 
In healthy normal cells, p53 remains in low levels and inactivated until triggered by internal or 
external stress signals. However, p53 becomes activated in response to stress via post-
translational mechanisms that increases its stability. p53 stabilization leads to its accumulation 
in the nucleus where it undergoes conversion to its active DNA binding form (Maki, 1999). 
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p53 stabilization has therefore been suggested to be, at least in part, due to phosphorylation and 
an inhibition of MDM2-mediated ubiquitination. DNA damaging agents are also thought to 
induce phosphorylation of p53 at multiple N-terminal sites leading to its stabilization (Shieh et 
al., 1997). Loss of the tumor suppressor, p53 function has been implicated in almost half of all 
human cancers (Hollstein et al., 1991).  When p53 is knocked out, multiple tumours developed 
in mice at a young age, suggesting its crucial role in tumour suppression (Donehow et al., 
1992).  
To date, two important negative regulators of p53 have been documented: RBBP6 and MDM2. 
RBBP6 has been suggested to target p53 for degradation by enhancing the activity of MDM2, 
the prototypical negative regulator of p53 (Pugh et al., 2006; Li et al., 2007). The section below 
describes the role of MDM2 and RBBP6 in the degradation of p53. Also, the abnormal 
expression of these proteins in tumorigenesis will also be outlined.  
1.5.1 MDM2: Negative regulator of p53 
MDM2, a well-characterized negative regulator of p53, is known to regulate the activity, 
stability and subcellular localization of p53. During unstressed conditions MDM2 binds p53 at 
the N-terminus, which impedes the ability of p53 to transactivate target genes such as p21.  The 
RING domain of MDM2 is predicted to contain a nuclear export signal that mediates the export 
of p53 from the nucleus into the cytoplasm, excluding p53 from acting as a transcription factor 
in the nucleus (Boyd et al., 2000). Also, MDM2 in the cytoplasm can function as an E3 
ubiquitin ligase targeting p53 for degradation at the proteasome (Rodriquez et al., 2000).  
In response to DNA damage, p53 is phosphorylated by ATM leading to destabilization of the 
MDM2: p53 complex, causing p53 to detach from MDM2 and localize to the nucleus (Yang et 
al., 2004). In most tumours with either mutant p53 or wildtype p53, MDM2 is overexpressed 
causing the p53-pathway to be inhibited. Western blot analysis of untreated MCF-7 breast 
cancer cells (wildtype p53) showed the overexpression of MDM2 with little or no expression 
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of p53. However, when these cells were exposed to cyclohexamide (inhibits eukaryotic 
translaton) for 1 hour, there was an observed decrease in MDM2 expression with an increase 
in p53 expression (Obrig et al., 1971; Peng et al., 2001). This suggest that overexpression of 
MDM2 results in the depletion of p53 and vice versa, which implies a negative regulation loop.  
1.5.2 RBBP6: Negative regulatory role to p53  
 
Retinoblastoma binding protein 6 (RBBP6) has been suggested to be essential for chaperone-
mediated ubiquitination of p53. Under normal conditions, RBPP6 targets p53 for degradation 
by MDM2 through its RING finger-like domain (Figure 3) (Chen et al., 2013). When MDM2 
binds to p53 through its RING finger domain, RBBP6 is recruited to the MDM2: p53 complex 
enhancing the activity of MDM2, which further targets p53 for proteasomal degradation.  
The RBBP6 protein family has been well characterized in various species, including; in Homo 
sapiens as Retinoblastoma-binding Q-protein 1 (RBQ1) (Saijo et al., 1995), mice as p53 
associated cellular protein testis derived (PACT) (Simons et al., 1997) and also as proliferation 
potential protein-related (P2PR) (Witte and Scott, 1997). Furthermore, three transcripts have 
been reported in humans occurring due to alternative splicing and poly-adenylation: Isoforms, 
1, 2 and 3 with lengths, 6.1, 6.0 and 1.1 kb, respectively (Pugh et al., 2006).  
Overexpression of RBBP6 has been implicated in many cancers (Mbita et al., 2011). For 
example, the overexpression of RBBP6 with p53 mutations has been linked to colon cancer 
progression (Chen et al., 2013) suggesting RBBP6 as a potential target for therapy. A previous 
study showed that embryos lacking a functional RBBP6/PACT died early (Li et al., 2007), 
indicating an enhanced p53 activity in the absence of RBBP6.  
 
1.6 Role of chemotherapeutic drugs in cancer treatment  
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For decades, several therapeutic options have been approved for treatment of cancer patients. 
These include: surgery, radiotherapy, hormone therapy, stem cell transplant, and 
chemotherapy. The therapeutic option of interest in this study is chemotherapy. Most, 
chemotherapeutic agents induce cell death through a p53-dependent mechanism, they include; 
dihydrofolate reductase inhibitors, 5-fluorouracil and topoisomerase I and II poisons such as 
irinotecan (Dive and Hickman, 1991). However, these chemotherapeutic drugs have been 
found to have limited specificity between cancer and normal cells since they target DNA 
replication-a normal physiological process (Bruce et al., 1966).  
Frequent side-effects of anticancer drugs include anemia, hair loss, digestive symptoms such 
as diarrhea, nausea, vomiting and abdominal pains caused by toxicity to intestinal 
mucoepithelial cells (Tanaka et al., 2008). Furthermore, cytotoxic chemotherapy given to pre-
menopausal women can lead to follicle destruction, ovarian fibrosis, progressive and premature 
ovarian failure and a reduction in oestrogen and progesterone levels which also contribute to 
risk of sterility. These drugs were also found to cause abnormalities in an exposed foetus and 
mutate genetic material (Chasle and How, 2003). 
Finding new ways of selectively targeting cancer cells without harming normal cells is 
imperative. A recent study suggested that toxic side effects on normal cells can be 
reduced/eliminated by boosting OXPHOS, the preferred metabolic pathway seen in normal 
healthy cells. Hull and Ntwasa (2010) showed that when female fruit flies (Drosophila 
melanogaster) were exposed to camptothecin alone adverse effects were observed on the 
reproductive system as only 20% of their embryos developed into pupae. However, when 
camptothecin was used in combination with methyl pyruvate -an OXPHOS boosting agent-, 
embryonic development was improved as 40% of embryos from treated mothers developed 
into pupae.  
B. Monchusi: PhD Thesis  
29 
 
In this current study, irinotecan, a derivative of camptothecin (CPT) has been used as a 
chemotherapeutic agent. Irinotecan has improved water solubility and pharmacokinetic 
characteristics compared to camptothecin (Garcia-Carbonero and Supko, 2002). 
1.7 Irinotecan: Pharmacodynamics 
 
About 30 years ago, CPT was discovered as an antitumour alkaloid from the Chinese tree, 
Camptotheca acuminate (Pommier et al., 1998). However, due to its poor aqueous solubility 
and unpredicted toxicity, the development of CPT as an anticancer agent was hindered. 
Irinotecan, a more hydrosoluble compound with a better toxicity profile than the parent 
compound, was used from the '80s. Irinotecan has been used effectively for the treatment of 
many cancers such as: uterine, ovarian, lung, colorectal, gastric and malignant lymphoma 
(Tanaka et al., 2008).  
Irinotecan is an ester prodrug and needs to be converted to its active metabolite SN-38 by a 
carboxyl esterase converting enzymes (Chung et al., 2007).  The improved water solubility of 
SN-38 is due to a dibasic bispiperidine substituent linked through a carbonyl group to the 
hydroxyl at C-10 (Figure 5) (Garcia-Carbonero and Supko, 2002). Irinotecan targets DNA 
replication by inhibiting the enzymatic complex of topoisomerase I-DNA in the nucleus 
(Lorusso et al., 2010). Irinotecan (CPT-11) inhibitory activity is predicted to be at position 20 
of its chiral carbon (C20) for topoisomerase I (Garcia-Carbonero and Supko, 2002). 
 
The principal enzymatic activity of topoisomerase I (Topo1) is to cut and re-ligate single 
stranded DNA (Stewart and Schutz, 1987). Topo1 has been shown to exclusively covalently 
bind double-stranded DNA at the 3'-phosphate end of the DNA strand, through a reversible 
transesterification reaction, creating a cleavable complex (Garcia-Carbonero and Supko, 2002).  
CPT and its derivatives stabilise this cleavable complex, resulting in the inhibition of the re-
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ligation of cleaved DNA (Hsiang and Liu, 1988).  The formation of double stranded breaks 
induces apoptosis (Lorusso et al., 2010).  
 
 
Figure 5: Chemical structure of irinotecan (7-ethyl-10-[4-[1-piperidino]-1-piperidino] 
carbonyloxy campothecin) and its metabolites, modified from Rivory, (1996). (a) Phase I metabolic 
reaction involves the formation of the active metabolite SN-38 by the carboxylesterases. (b) The phase 
II reaction involves the glucuronidation of 7-ethyl-10-hydroxy-camptothecin (SN-38) by cytochrome 
UGT to SN-38 β- glucuronide. SN-38 is eliminated when it is transformed to its glucuronide form.  
 
 
1.7.1 Pharmacokinetics of irinotecan 
 
Irinotecan is present in aqueous solution as a lactonic and hydroxy acid form. The intact 
lactonic ring of irinotecan is essential for its passive diffusion into tumour cells (Lorusso et al., 
2010). The adsorption, distribution, metabolism and excretion (ADME) of total irinotecan and 
SN-38 have been shown clinically to differ amongst patients. SN-38 volume distribution is 
large (100 - 300 L/m2) indicating extensive tissue penetration with a relatively long half-life of 
B. Monchusi: PhD Thesis  
31 
 
6 to 30 hours thereby increasing its efficacy.  The plasma protein binding of irinotecan is low 
- 30 - 43% but significantly higher for SN-38 in the range 92 - 96% (Rivory, 1996).   
Glucuronidation and biliary excretion are the main mechanisms of SN-38 metabolism and 
subsequent elimination from the body. Renal excretion is also a means of SN-38 elimination, 
however to a lesser extent (Garcia-Carbonero and Supko, 2002). Phase I metabolic reaction 
starts conversion of the ester prodrug (irinotecan) to SN-38, the active metabolite by the 
carboxylesterases in the liver (Chung et al., 2007). Phase II metabolic reaction involves the 
glucuronidation of SN-38 to SN-38 β-glucuronide by the uridine diphosphate 
glucuronosyltransferase (UGT) (Bosman et al., 1995). The phase II reaction has been 
implicated for the adverse effects observed in patients after irinotecan (CPT-11) therapy 
(Jonsson et al., 1997). Studies have shown grade 3 and 4 neutropenia occurs in 14 – 47% of 
patients treated once every three weeks with irinotecan (125mg/m2) (Garcia-Carbonero and 
Supko, 2002).  
 
1.7.2 Clinical implications of irinotecan 
 
Irinotecan, given orally once a day for 5 days every 3 weeks has been shown to cause adverse 
side effects. Myelosuppression is one of the commonly encountered toxic effect of irinotecan 
(Garcia-Carbonero and Supko, 2002). In addition to myelosupression, irinotecan therapy is 
associated with two major side effects: insidious and cholinergic (Rivory, 1996). Cholinergic 
side effects occur within the first 24 hours after irinotecan administration and results from an 
inhibition of acetylcholinesterase activity. Symptoms include hypersalivation, abdominal 
cramps, diarrhea, visual accommodation disturbance, lacrimation, and rhinorrhea (Garcia-
Carbonero and Supko, 2002). Insidious side effects are unknown but are suggested to be due 
to high concentrations of SN-38 in the gastrointestinal tract (Rivory, 1996).  
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The table below summarizes the dose schedule given to patients with different types of cancers 
resulting in grade 3- 4 toxicities (Table 1). The toxic side effects associated with irinotecan 
administration stresses the need for an adjunct agent for selective induction of apoptosis in 
cancer cells. 
 
Table 1: Dose schedule of irinotecan administered to cancer patients. Adapted from Garcia-
Carbonero and Supko, (2002) . 
Disease No. of patients Dose and schedule Response rate (%) Grade 3-4 
toxicities (%) 
Cervical cancer  42 125 mg/m2, 90 min 
weekly x 4 w 
21  Neutropenia: 36% 
Diarrhoea: 24% 
Vomiting: 45% 
Anaemia: 62% 
Ovarian cancer  55 100 mg/m2  2w 90 
min 
24 Leukopenia: 87% 
Diarrhoea: 44% 
Vomiting: 60% 
Anorexia: 67% 
Non-small-cell 
lung cancer  
122 100 mg/m2 90min  21 Neutropenia: 8% 
Diarrhoea: 15% 
Small-cell lung 
cancer  
35 100 mg/m2 90min  37 Not reported 
Colorectal cancer  48 300 mg/m2  30 min 
3 w 
19 
 
Neutropenia: 48% 
Diarrhoea: 35% 
Vomiting: 13% 
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1.8 Methyl pyruvate as a potential adjunctive to irinotecan  
 
By passing glycolysis is a good chemotherapeutic strategy as cancer cells are dependent on it. 
In this study the glycolytic pathway was bypassed using exogenous methyl pyruvate, instead 
of pyruvate as it is unstable and has by products that inhibit OXPHOS. Pyruvate, once in 
aqueous solution, undergoes an aldo-like condensation reaction to form 2-hydroxy-2-methyl-
4-ketoglutarate also known as parapyruvate (Montgomery and Webb, 1956; Von Kroff, 1964). 
Additionally, in aqueous solution, pyruvate has been shown to be a mitochondrial poison as it 
undergoes spontaneous cyclization and dehydration to form enolic lactone form or non-
enzymatic reduction to form 2,4-duhydroxy-2-methylglutarate (Willems et al., 1978).  
Furthermore, exogenous methyl pyruvate is more lipophilic, aqueous soluble and stable than 
pyruvate (pyruvic acid) with better pharmacokinetic properties (Figure 6) (Nishida et al., 
2014). To date, methyl pyruvate has been used and patented for treatment of diseases of the 
nervous system (US 20060052448 xA1). Increasing pyruvate levels may bypass glycolysis, 
boosting OXPHOS. Methyl pyruvate has been shown to activate the respiratory chains in 
pancreatic β- cell for ATP production (Duchen et al., 1993). A study done by Hull and Ntwasa 
(2010) on female fruit flies has shown that a glycolytic flux occurs during recovery from 
camptothecin alone. However, when methyl pyruvate was used in combination with 
camptothecin, they were protected and embryonic development improved. This observation 
hints that a combined therapy of irinotecan and methyl pyruvate might protect normal cells 
during chemotherapy. In this study exogenous methyl pyruvate, an analog of pyruvate was 
used in combination with irinotecan.  
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Figure 6:   Methyl pyruvate is an analog of pyruvate with an added methyl group (CH3) 
synthesized through a methylation reaction.  
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1.9 Justification of Study 
Warburg (1956) initially proposed that reversal of the Warburg Effect in cancer cells would 
kill cancer and protect normal cells even during chemotherapy. This study is necessary to 
investigate the molecular basis of this phenotype using exogenous methyl pyruvate.  
 
1.10 Aims  
 
1. To reverse the Warburg Effect in lung and breast cancer cells by boosting OXPHOS to 
promote death while rescuing normal lung fibroblast cells from irinotecan-induced cell 
death.  
2.  To elucidate the molecular mechanisms involved during treatment of normal and 
cancer cells with the various treatments and to characterise the phenotypes observed in 
cancer and normal cells by boosting OXPHOS.   
 
1.11  Objectives 
 
1. To evaluate cell viability and cytotoxicity of methyl pyruvate and irinotecan-treated 
cancer cell lines (human lung and breast) and a normal cell line using xCELLigence 
technology 
2. To determine the type of cell death and cell cycle changes on cancer cells and normal 
cells during various treatments and recovery using flow cytometry 
3. To determine the effects of the various treatments on expression profiles of pro-
apoptotic and anti-apoptotic genes by RT-PCR and western blot analyses 
4. To determine pathways affected by the drug combination (irinotecan and methyl 
pyruvate) in A549 lung cancer cell line and MRC-5 normal lung fibroblast cell line 
using RT2 PCR microarray 
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Chapter 2: Materials and Methods  
             
2.1 Materials 
 
All reagents, primers, antibodies, kits, and softwares used for this study are included in 
Tables A1 – A8 in the appendices section.   
 
2.2 Methods 
 
2.2.1 Cell culturing 
 
In this study Human Lung Adenocarcinoma (A549, wildtype p53; ATCC® CCL-185TM), breast 
adenocarcinoma (MDA-MB 231, p53280R-K; ATCC® CRM-HTB-26TM) and lung embryonic 
fibroblast (MRC-5, wildtype p53; ATCC® CCL-171TM) cell lines were utilised. All of the 
above mentioned cell lines were maintained and grown in DMEM (Dulbecco's Modified 
Essential Medium) growth media supplemented with 10% Fetal Bovine Serum and 1% 
penicillin/streptomycin at 37ºC with 5% CO2.  
2.2.2 Cell viability assay using the xCELLigence system during and after treatment 
 
The xCELLigence system is a real-time cell analyzer that continuously monitors cell 
attachments by measuring electrical impedance. As cells grow and spread while attached to the 
surface of the plate, their impedance measurements are displayed as cell index (CI) values. The 
CI calculates the number of live cells as they interact with the electrodes on the E-plate over a 
period of time. When cells are not present on the electrodes, the CI is zero. As the number of 
cell attachments increases so does the CI values, and changes in cell adhesion and cell viability 
lead to change in CI. The cell index values give us a clear picture of the cell number and the 
biological status of the cells. Normalized cell index (y-axis) as a function of time (x-axis) was 
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used to plot cell growth. Normalized cell index (NCIti) was calculated as the cell index (CIti) at 
a given time point divided by the cell index at the normalized time point (CInml_time) ( NCIti = 
CIti / CInml_time).  
Cells were seeded at optimum cell densities of 1 x 104 for MDA-MB 231 and MRC-5 cells and 
5 x 103 for A549 cells into 16-well gold coated microelectrode E-plates until cell growth 
reached a logarithmic phase.  Subsequently, the following final concentrations were added to 
each well: 0.5 µM irinotecan, 1 mM and 2 mM methyl pyruvate. Survival analysis studies on 
Drosophila melanogaster showed that exposure to 10% methyl pyruvate was toxic but at 5 % 
methyl pyruvate the survival rate increased (Nweke, 2015). Taking into consideration that the 
flies were only exposed to these concentrations of methyl pyruvate by mixture with food, we 
then used (1 mM and 2 mM methyl pyruvate) in this study. Growth patterns based on the 
various treatments were analyzed up to 48 hours. For recovery of MRC-5 cells, the media was 
replaced after 20 hours. Untreated cells served as a positive control. Results were shown as 
time-dependent cell response dynamic curves reported as average values for each cell line. The 
results reported for each series of treatments including the untreated were performed in 
duplicates for each cell line.  
2.2.3 Flow cytometry  
 
i) Apoptosis detection 
 
Results obtained from the xCELLigence experiments showed that 0.5 µM irinotecan in 
combination with 2 mM methyl pyruvate was the optimal concentration for effectively killing 
the three cancer cell lines used while allowing the survival of normal MRC5 cells. To determine 
the mode of cell death induced by the various treatments, apoptosis detection was performed 
using the Annexin-V FITC kit. The Annexin-V FITC kit includes Annexin-V conjugated FITC 
staining solution, propidium iodide staining solution and the 10X binding buffer. During 
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apoptosis plasma membrane integrity is lost and a phospholipid, phosphatidylserine (PS), 
translocates from the inner plasma membrane to the outer leaflet followed by condensation of 
the cytoplasm and nucleus. Annexin-V a Ca2+ -dependent phospholipid binding protein has 
high affinity for PS. Annexin-V fluorochrome (FITC) can be used for the detection of exposed 
PS which is characteristic of early apoptotic cells using flowcytometry. Propidium iodide can 
detect late apoptotic cells characterized by permeable membranes. Viable cells remained 
unstained by either PI and Annexin-V.  
Cells were treated with 2 mM methyl pyruvate in the presence and absence of 0.5 µM 
irinotecan, harvested at 4, 24 and 48 hours and rinsed twice with 1X PBS. Subsequently, cells 
were pelleted and re-suspended in 1X binding buffer at a concentration of 1 x 106 cells/ml and 
incubated with 5 μl of Annexin V-FITC and 10 μl propidium iodide for 10 minutes in the dark 
at room temperature. The samples were immediately analyzed using the BD AccuriTM C6 flow 
cytometer to determine the percentage of viable, apoptotic and necrotic cells.   
ii) Cell cycle analysis 
 
We determine the stages of cell cycle at which the drugs used were effective. The FxCycle 
PI/RNase staining solution was used to analyse DNA content of fixed cells after treatment. The 
FxCycle PI/RNase staining solution consists of propidium iodide staining solution, RNase A 
and a permeabilization reagent. Propidium iodide is a red fluorescent dye that binds to DNA 
by intercalating between bases. The amount of DNA present is proportional to the fluorescence 
intensity in each stained cell. Since propidium iodide binds both DNA and RNA, it was 
necessary to add an RNase reagent.  The fluorescence intensity in the G2/M phase is expected 
to be doubled (4n) compared to the G0/G1 phase (2n), and the S phase is expected to be more 
than 2n but less than 4n. DNA damaging agents can cause interruption of cell cycle progression 
at certain check points to allow DNA repair and to prevent carcinogenesis. 
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Approximately 3 x 106 cells/ml were treated with 2 mM methyl pyruvate in the presence and 
absence of 0.5 µM irinotecan and harvested at 4, 24 and 48 hours. Cells were harvested and 
detached using trypsin and the samples were centrifuged at 4°C for 15 minutes at 5000 xg. 
Subsequently, the supernatant was decanted and the pellet washed with pre-chilled 1X PBS.  
The cells were mixed with 300 µl of 1X PBS and fixed with 70% ethanol to permeabilise the 
cells allowing entry of propidium iodide. Once all fixatives were removed by centrifugation at 
5000 xg for 10 minutes at 4°C, the pellets were stained with FxCycle PI/RNase staining 
solution. This was used to quantify DNA in each part of the cell cycle. The samples were then 
left in the dark at room temperature for 30 minutes and analysed using the BD AccuriTM C6 
Flow Cytometer.  
2.2.4 RNA extraction 
 
RNA was extracted using the TRIzol method. Cells were treated and harvested as previously 
described in section 2.2.3. The cells were rinsed twice with 1X PBS and detached using trypsin. 
This was followed by centrifugation at 1000 xg for 5 minutes to pellet cells. To each pellet, 
300 µl of the TRIreagent® was added to lyse the cells. Cells were then resuspended and 
vortexed for 10 seconds. All the tubes were then left on ice for 5 minutes. For phase separation 
of samples, 60 µl of chloroform, was added and allowed to stand at room temperature for 10 
minutes and centrifuged at 12000 xg for 15 minutes.  The aqueous phase was removed and 
placed in a clean tube. To precipitate the RNA, 150 µl of isopropanol was added into each tube 
and followed by incubation for 5 minutes at room temperature. The samples were then 
centrifuged at 12000 xg for 10 minutes at 4ºC. The supernatant was discarded and 150 µl of 
70% ice cold ethanol was added to wash the RNA pellet. The ice-cold ethanol was discarded 
after centrifugation at 12000 xg for 5 minutes. Tubes were opened and inverted for 5-7 minutes 
and then placed in a heating block for 3 minutes at 50ºC to dry pellet. To dissolve the RNA 
pellet, 50 µl of nuclease free water was added. The Nanodrop was then used to quantify and 
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check the quality of the RNA. All samples were of good quality as the A260 /A280  was above 
1.8.   
2.2.5 Reverse transcriptase polymerase chain reaction 
 
For each reaction 1 µg of total RNA was added to each tube. The following reagents were 
added to make up the reaction mix; total RNA (1 µg), oligo (dT) primer (2 µl), nuclease-free 
water (x µl), M-MuLv reaction mix (10 µl) and M-MuLv enzyme mix (2 µl) to make up a total 
volume of 20 µl. cDNA synthesis involved; 1 cycle for 60 minutes at 42°C followed by 72°C 
for 5 minutes and 4°C to cool the samples.   
For the amplification of the desired gene, the 4 µl cDNA obtained by reverse transcription was 
combined with 25 µl of 2X PCR master-mix, 0.2 µM of forward primer, 0.2 µM of reverse 
primer and 19 µl nuclease free water was added to make up a final volume of 50 µl. 
Subsequently, the transcripts; BID, Bax, p21, caspase 3, MDM2 and the housekeeping gene, 
GAPDH underwent the following cycles: 94°C initial denaturation for 1 minute, 35 cycles 
(94°C denaturation for 30 seconds, annealing for 30 seconds, extension at 72°C for 1 minute 
and a final extension cycle at 72°C for 5 minutes). 
The amplification products obtained from reverse transcription PCR were electrophoresed at 
120 V on a 1% agarose gel using ethidium bromide as dye. The Chemidoc MP Imaging system 
was used to visualize the gel.  
2.2.6 Western blot procedure 
 
Equal amounts of whole cell protein were extracted with RIPA buffer (50 mM Tris-HCl, pH 
8.0, 150 mM sodium chloride, 1.0% NP-40 (nonyl phenoxypolyethoxylethanol), 0.5% sodium 
deoxycholate, and 0.1% sodium dodecyl sulfate) from treated and untreated cells. For lysate 
preparation from each culture of both treated and untreated cells, RIPA was directly added to 
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cell monolayer and allowed to stand on ice for 5 minutes. A cell scraper was used to detach 
cells from the surface. Each sample was resuspended and centrifuged at 4°C, 5000 xg for 10 
minutes to pellet. Pellets containing the protein were then washed with ice-cold 1x PBS. 
Sodium dodecyl sulfate gel was performed as per protocol described by Laemmli (1970). 
Approximately 20 µl of the protein samples were loaded onto the gel after they were heated in 
1X SDS-PAGE sample buffer at 95°C for 5 minutes. Cellular proteins were separated on the 
basis of charge at 130 V for approximately 90 minutes.  
The Hoefer VE blotting mini system was used to transfer proteins from the SDS gel to PVDF 
membrane (Amersham Hybond-P). Transfer was undertaken at 70V for 1 hour 30 minutes. The 
membranes were then blocked with SuperBlock® protein blocking buffer (Thermo Scientific) 
to prevent non-specific binding of proteins. After washing five times (5 min/ per wash) with 
1X PBS-Tween, the membranes were probed with primary antibodies of protein of interest as 
listed in Table 8 overnight at 4°C. The primary antibodies were removed and the membranes 
washed 5 times (5 min/ per wash) in 1X PBS-Tween.  The membranes were incubated for 1 
hour at room temperature with their respective appropriate secondary antibodies as listed in 
table 8 to bind specifically to the relevant primary antibody. Afterwards, washes were done for 
5 minutes with 1 X PBST at room temperature. SuperSignal® West Pico Chemiluminescent 
Substrate (Thermo Scientific) was then added to each blot in a 1:1 ratio (Lumino/Enhancer and 
Stable peroxide buffer) and incubated for 5 minutes in the dark. The signal detected from the 
protein-antibody complex using the Bio-Rad imaging system was proportional to the 
concentration of the proteins present on the membrane.  
2.2.7 Western blot for RBBP6 
 
RBBP6 protein family is highly positively charged at the C-terminus (Simons et al., 1997). It 
is therefore difficult to separate on 12% SDS-PAGE gel, as it does not enter the SDS gel. After 
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careful consideration of the options, an 8% separating gel was used, to facilitate its entry into 
the gel. The 201 kDa and 13 kDa bands were then separated by SDS-PAGE. The stacking gel 
composition remained the same as described in 2.2.6 Western blot procedure was performed 
as previously described in section 2.2.6. Membranes were incubated with anti-RBBP6 rabbit 
polyclonal (1:500) primary antibody diluted with 1X PBS Tween overnight. This was followed 
by 1 hour incubation in anti-rabbit polyclonal IgG (1:5000) secondary antibody. Membrane 
was washed 5 x (5 min/ per wash) with 1X PBS-Tween. SuperSignal® West Pico 
Chemiluminescent Substrate (Thermo Scientific) was used as described in prevous section to 
detect signal.  
2.2.8 RT2 profiler PCR array gene expression analysis   
Our next objective was to look at pathway focussed gene expression profiling to determine 
which pathways are altered by cotreatment in A549 and MRC-5 cells using the RT2 ProfilerTM 
PCR array Human Cancer PathwayFinderTM (QIAGEN- PAHS-033ZF-12).  This microarray 
includes 84 genes representative of 9 different biological pathways genes involved in 
tumorigenesis: angiogenesis, apoptosis, cell cycle control, cell senescence, DNA damage 
repair, invasion, metastasis, signal transduction molecules, and transcription factors. The PCR 
Array plate also includes controls to monitor genomic DNA contamination (GDC) as well as 
the reverse transcription controls (RTC) and the positive PCR controls (PPC). The RT2 profiler 
PCR array provides a platform for analysing the expression of a focused panel of genes found 
to be differentially expressed during various treatments.  
i. RNA Extraction 
A549 lung cancer and MRC-5 normal lung fibroblast cells were treated with irinotecan (0.5 
µM) combined with methyl pyruvate (2 mM) for 48 hours.  Total RNA was isolated as 
described in section 2.2.4 from both the treated and untreated cells. To eliminate DNA 
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contaminants from the isolated RNA, a DNA digestion was performed using a DNase kit (Siga-
AMPD1-1KT). To 50 µl of RNA, 5 µl of the 10 x reaction buffer and 5 µl of DNase I was 
added. This was followed by gentle mixing and incubation at room temperature for 15 minutes. 
To bind calcium and magnesium ions, 5 µl of the stop solution was added. Tubes were 
incubated at 70°C for 10 minutes to detach both DNase I and mature RNA. The total RNA was 
then suspended in 50 µl of RNase free water and placed on ice. The quality and quantity of 
total RNA was determined using the Nanodrop spectrophotometer (Thermo Fischer Scientific, 
California, USA). Total RNA was measured for all four samples and the 260/280 ratio was 
greater than 1.9, indicating good quality RNA.  
ii. cDNA synthesis using the RT2 first strand kit 
Prior to adding the reverse-transcription reaction, genomic DNA contamination mix was made 
containing 2 µg total RNA, 2 µl buffer GE, and RNase-free water (QIAGEN-129117) added 
to make up a 10 µl reaction, and incubated at 42°C for 5 minutes. cDNA synthesis was done 
using the RT2 First strand cDNA synthesis kit (QIAGEN-330401). In a 20 µl reaction 
containing 10 µl of DNA elimination mix and 10 µl of the reverse-transcription mix 
(components; 5 x buffer BC3: 16 µl, control P2: 4 µl, RE3 reverse transcriptase mix: 8 µl, 
RNase - free water: 40 µl) at 42°C for 15 minutes in the GeneAMP Thermal Cycler PCR system 
(Perkin Elmer-2400). The reaction was stopped by incubating at 95°C for 5 minutes. After the 
complete cycle, 91 µl of RNase-free water was added to each reaction. 
To confirm successful cDNA synthesis, RT-PCR was done on each sample with GAPDH, a 
housekeeping gene. 
Differential gene expression using RT2 profiler PCR array format F 
The RT2 ProfilerTM PCR array Human Cancer PathwayFinderTM (QIAGEN- PAHS-033ZF-12) 
was used to profile differences in gene expression between A549 (untreated) and A549 (co-
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treated) cells and between MRC-5 (untreated) and MRC-5 (co-treated) cells after 48 hours. The 
following reagents were added into a 15 ml Falcon tube (QIAGEN; 990552) to make up a 2700 
µl cDNA amplification reaction; 1350 µl of the 2 x RT2 SYBR Green Mastermix (QIAGEN- 
330500), 102 µl cDNA synthesis reaction mix, and 1248 µl RNase-free water (QIAGEN-
129117). The PCR component mix were then placed in a reservoir (QIAGEN-338162) 
avoiding exposure to light. Using the INTERGA VIAFLO ASSIST liquid handler (Interga 
Biosciences - CH-7205 Zizers) 25 µl of the mix was added to each well in the array plate. Each 
plate was carefully sealed with clear optical adhesive film prior to the run and centrifuged at 
1000 x g for 1 minute at room temperature using the low speed benchtop centrifuge (Grant 
instruments - LCM-3000) to remove bubbles. The real-time cycle (Roche LC-480) conditions 
included; initial heating step to activate the HotStart DNA Taq polymerase for 10 minutes at 
95°C, and 45 cycles: 95°C for 15 seconds and 60°C for 1 minute. 
2.2.9  Bioinformatics analysis  
 
(i) Differential gene expression analysis 
Following each run, the threshold cycle (CT) for each well was obtained. Differentially 
expressed genes due to cotreatment were identified using the QIAGEN data analysis web 
portal (www.qiagen.com/za/shop/genes-and-pathways/data-analysis-center-overview-
page/rt2-profiler-pcr-arrays-data-analysis-center-
/?Instrument=Roche_480_96&format=F&catno=PAHS-033Z). CT values were normalized 
based on selection of reference genes that showed small changes in their expression across 
different sample groups (differences in CT < 1). In A549 lung cancer cells, HPRT1 
(Hypoxanthine phosphoribosyltransferase 1) was the selected reference gene in A549, while 
in MRC-5, ACTB (Actin, beta). These reference genes were selected because their expression 
remained unchanged in untreated and treated cells. The CT values for these genes were 
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geometrically averaged and used for the fold change ∆∆ CT calculations. Genes with greater 
than twofold change in gene expression was selected. The data analysis report was then 
exported as a pdf document.   
(ii)Pathway analysis of differentially expressed genes.  
(a)PANTHER classification system 
To identify the biological pathways affected by the combined treatment, the PANTHER 
classification system was used. PANTHER, which is part of the gene ontology reference 
genome project, is a publicly availably bioinformatics software (http://www.pantherd.org/) 
designed for gene function, ontology and pathway analysis. The PANTHER software is made 
up of 82 complete genomes organised into families and subfamilies, evolutionary relationships 
captured into phylogenetic trees, multiple sequence alignments and statistically models (such 
as the Hidden Markov model (HMM)) (Mi et al., 2013). The HMM score provides an 
estimation of the confidence level of the classification where the query list is assigned to the 
best scoring HMM (Thomas et al., 2003). Genes are classified according to their functions and 
assigned to PANTHER pathways using GeneOntology and PANTHER databases. 
 (b) REACTOME pathway analysis 
The REACTOME software tool (http://www.reactome.org ) was also used for pathway 
analysis. REACTOME is a curated, open access, open source, and peer-reviewed biological 
database of human pathways and reactions that closely simulate the actual physical interactions 
occurring within a cell. REACTOME provides an archive of biological processes and a 
platform for discovering unexpected functional relationships from gene expression patterns in 
tumour cells (Croft et al., 2013). Small molecule entities, proteins, reactions, and pathways in 
REACTOME are cross referenced with accession numbers and identifiers from well-
established databases including: Ensemble, Uniprot databases, NCBI, UCSC Genome browser, 
and ChEBI (Milacic et al., 2012). This database includes annotations for 7088 of the 20 774 
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protein-coding genes in the current Ensemble human genome assembly (34% coverage), 1421 
small molecules organized into 6744 reactions collected in 1481 pathways, and 15 107 
literature references (Croft et al., 2013).     
Differentially expressed genes identified from this study were used as input into this software 
and a pathway overview diagram generated.  Pathways were considered statistically enriched 
when the p < 0.05 indicated by bright red colour. Furthermore, pathways upregulated was 
indicated by dark green colour while those downregulated were indicated by a bright yellow 
colour. 
(iii) Network-based gene expression analysis 
GeneMANIA through Cytoscape plugin was used to determine whether changes in gene 
expression due to cotreatment, described previously in A549 and MRC-5 cells will reflect 
possible changes in the function of certain biological processes. GeneMANIA Cytoscape 
plugin is a standalone tool implemented in java and freely available 
(www.genemania.org/plugin/). GeneMANIA displays an interactive functional association 
network by extending the query gene list with genes that are functionally similar in order to 
show the relationships among genes from a data set. Each network (individual dataset) in the 
basic algorithm is assigned a weight based primarily on how well connected genes are to each 
other compared with their connectivity to non-query genes, down-weighing redundant 
networks (Warde-Farley et al., 2010). Interactions were considered statistically significant 
when q < 0.05. A q-value of 0.05 indicates that there is a 5% chance of getting a false 
statistically significant result. The q-values were estimated by the in-built Benjamini-Hochberg 
procedure. 
GeneMANIA contains over 800 networks for six organisms: Arabidopsis thaliana, 
Caenorhabditis elegans, Drosophila melanogaster, Mus musculus, Homo sapiens and 
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Saccharomyces cerevisiae which are grouped into co-expression, genetic interaction, 
colocalization, physical interaction, shared protein domain and predicted categories (Montojo 
et al., 2010).  In this study the Homo sapiens network was used for analyses. Datasets that are 
publicly available are accessed by GeneMania, such as physical and genetic interaction data 
from BioGRID (Breitkreutz et al., 2008), co-expression data from Gene Expression Omnibus 
(GEO) (Barrett et al., 2009), pathway and molecular interaction data from Pathway Commons 
(http:// www.pathwaycommons.org), and protein predicted interaction data based on ontology 
from I2D (Brown and Jurisica, 2005). 
The query list containing differentially expressed genes found to be uncommon between A549 
and MRC-5 cells was uploaded which consisted of gene name symbols. Networks were 
exported as PNG files and descriptive information as text files.  
2.2.10  Statistical analysis 
All statistical analyses were performed using the Graphpad software. Results were expressed as 
the mean value ± SEM of at least three independent experiments. Statistical analysis was 
performed with the paired student t-test comparing two groups at a time. P-value < 0.05 was 
set and was considered statistically significant. 
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Chapter 3: Results 
             
3.0 Introduction 
The main objective of this study was to exploit the phenotypic differences between cancer and 
normal cells to deduce a strategy for selectively killing cancer cells. Otto Warburg was the first 
to  propose that cancer cells prefer the glycolysis pathway while most normal cells favour the 
oxidative phosphorylation (OXPHOS) pathway for glucose metabolism, even in the presence 
of oxygen (Warburg, 1956). In this study, exogenous methyl pyruvate was used to enhance 
OXPHOS and reverse the Warburg effect. Using Drosophila as a model organism, colleagues 
from our group found that there was a 40 % increase in embryos developing into pupae when 
females were exposed to camptothecin combined with methyl pyruvate, compared to those that 
were exposed to camptothecin alone (Hull and Ntwasa, 2010). This observation prompted the 
investigation to confirm the protective role of methyl pyruvate on normal cells during 
chemotherapy. Due to the poor aqueous solubility and toxicity of camptothecin, irinotecan was 
used in this study as a DNA damaging agent. Irinotecan is a water-soluble derivative of 
camptothecin presently used for the treatment of colon and ovarian cancer (Chung et al., 2007).  
It was observed that introduction of exogenous methyl pyruvate protected   normal cells from 
irinotecan-induced cell death. Exogenous methyl pyruvate combined  with irinotecan were 
more effective in killing A549 lung cancer cells expressing wild type p53 than in MDA-MB 
231 cells expressing mutant p53. In A549 lung cancer cells after introduction of exogenous 
methyl pyruvate, death was mainly by apoptosis with most cells accumulated at the sub G0/G1 
phase, indicating cell death. However,  an opposite cell death mechanism was observed in  
MDA-MB 231 cells as  both necrosis and apoptosis were observed, with most  cells 
accumulating at the G0/G1 phase and the sub G0/G1  phase, indicating cell cycle arrest and cell 
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death. In MRC-5 cells, in contrast to cancer cells, introduction of exogenous methyl pyruvate 
resulted in an increase in live cells, with most cells accumulating at the G0/G1 phase, S-phase, 
and the G2/M phase.  
RT-PCT and Western blot analyses revealed that after introduction of exogenous methyl 
pyruvate death was mainly p53 - dependent in A549 cells while in MDA-MB 231 death was 
through another caspase-independent and p53-independent pathways. In MRC-5 cells the 
introduction of exogenous methyl pyruvate abrogated the p53/p21 axis, switching off the 
apoptotic pathways. Through pathway focussed gene expression profiling, exogenous methyl 
pyruvate combined with irinotecan induced genes that mostly mediate the programmed cell 
death pathway in A549 cells while in MRC-5 cells genes that mediate cell survival and 
angiogenesis were induced.   
 
3.1 The effect of interfering with OXPHOS on cell proliferation  
 
To determine the effect of enhancing OXPHOS on cancer and normal cells   various 
concentrations of exogenous methyl pyruvate were combined with irinotecan and the 
proliferation profiles of the cells were monitored in the non-invasive label-free xCELLigence 
RTCA (real-time cell analysis) platform. Two cancer cell lines; A549 (p53+/+) and MDA-MB 
231 (p53R280K) and MRC-5 cells, a normal lung fibroblast cell line, were grown to exponential 
phase and treated as described in section 2.2.2. The xCELLigence technology uses 
interdigitated gold microelectrodes to monitor viability of cultured cells. Normalized cell index 
(y-axis) as a function of time (x-axis) was used to plot cell growth. Data reported here is a 
representative of an average of 2 independent experiments of each cell line.  
The toxic effect of irinotecan on normal cells was evident when cells were treated with 0.5 µM 
irinotecan alone. Cell proliferation of cancer cells (A549 and MDA-MB 231) as well as the 
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MRC-5 normal fibroblasts cells was inhibited, as indicated by a rapid reduction in cell index 
post treatment (Figure 3.1). Irinotecan is a topoisomerase poison known to kill cells by acting 
at the S-phase of the cell cycle thereby interfering with DNA replication (Lorusso et al., 2010). 
Topoisomerase I (Topo1) mechanism of action   involves cutting and re-ligating single stranded 
DNA (Stewart and Schutz, 1987). Topo1 has been shown to exclusively covalently bind 
double-stranded DNA at the 3'-phosphate end of the DNA strand, through a reversible 
transesterification reaction, creating a cleavable complex (Garcia-Carbonero and Supko, 2002). 
 Treatment with 2 mM methyl pyruvate combined with 0.5 µM irinotecan compared to 0.5 µM 
irinotecan alone, inhibited cell proliferation of both cancer cells  (Figure 3.1 A and B)  but 
protected  MRC-5 normal fibroblast cells (Figure 3.1 C) from irinotecan-induced cell death. 
Interestingly, even when the drugs were removed, MRC-5 cells survived the irinotecan 
treatment and did not die (Figure 3.1 D). Treatment with 1 mM exogenous methyl pyruvate 
alone and combined  with 0.5 µM irinotecan was less effective in killing cancer cells as  in 
both cancers  as the cell index after 20 hours post treatment did not reach zero, similar to MRC-
5 normal cells, suggesting cell proliferation (Figure 3.1). It is noteworthy that treatment with 2 
mM methyl pyruvate alone was still able to inhibit cell proliferation in both cancer cells, while 
no changes were observed in MRC-5 cells as the cell index remained constant over time.   
These results suggest that introduction of 2 mM exogenous pyruvate alone and in the presence 
of 0.5 µM irinotecan is able to kill cancer cells while protecting normal cells. These 
concentrations were therefore used for further studies.  
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Figure 3.1 Introduction of exogenous methyl pyruvate protects normal MRC-5 cells from cell 
death Real-time analysis of cell viability of A549 (A), MDA-MB 231 (B), MRC5 (C) and MRC5 (D) 
for approximately 30 hours post-treatment using xCELLigence technology. A549 and MDA-MB 231 
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cells were treated for approximately 48 hours after growth curves reached a logarithmic phase. MRC5 
cells (C) were treated and grown as other cell lines in real time while MRC5 cells (D) were treated for 
20 hours then DMEM was replaced with fresh DMEM-nutrient supplemented medium and was allowed 
to grow for a further 24 hours for recovery. A time dependent plot (x-axis) with 8-hour intervals, 
representative of changes in normalized cell index (y-axis) were recorded and used to indicate cell 
attachment. Data were normalized, indicated by the vertical line at 14 hours for A549 and MDA-MB 
231 cells, and 3 hours for MRC-5 cells. The following letters were used to present the combined 
treatment, Ir; irinotecan and Mp; methyl pyruvate. Arrows on each figure show time points at which 
treatments were added and the asterisk symbol, when fresh DMEM nutrient supplemented medium was 
added to MRC-5 cells during recovery (D). 
 
3.2 Exogenous methyl pyruvate reduces apoptosis in irinotecan-treated 
normal cells 
 
From the xCELLigence results, introduction of 2 mM methyl pyruvate alone and combined 
with 0.5 µM irinotecan was effective in killing both cancer cells (A549 and MDA-MB 231) 
while promoting proliferation of normal MRC-5 cells. Next, the mechanism by which cell 
survival in normal cells and cell death in cancer cells occurred after introduction of exogenous 
pyruvate were investigated by assessing the mode of cell death and cell cycle changes. This 
was important since xCELLigence RTCA system does not distinguish between the types of cell 
death induced. It only measures cell proliferation and death.  
The Annexin-V FITC apoptosis kit was used to determine the mode of cell death induced 
following treatment with permutations of exogenous methyl pyruvate and irinotecan. Two 
cancer cell lines, A549 with wild type p53 and MDA-MB 231 with mutant p53 and one normal 
fibroblast cell line (MRC-5) with wild type p53, were used. These two different p53 statuses 
were important as almost half of all cancers harbours a p53 mutation (Wallace-Borduer and 
Lowe, 1999). Cells were treated with 0.5 µM irinotecan in the presence and absence of 2 mM 
exogenous methyl pyruvate and harvested at different time intervals (4, 24, and 48 hours) after 
treatment.   
Throughout all treatments, death was mainly by apoptosis in A549 cancer cells with wild type 
p53 while  in MDA-MB 231 cells with mutant p53 most cells died by necrosis (Figure 3.2 A 
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and B). Introduction of exogenous methyl pyruvate combined with irinotecan was most 
effective in killing A549 cells compared to all other treatments. Interestingly, exogenous 
methyl pyruvate alone killed more MDA-MB 231 cells than all other treatments.  
Approximately, 80.3% of apoptotic cells and only 0.5% of necrotic cells were observed after 
48 hours treatment with exogenous methyl pyruvate alone in A549 cells (Figure 3.2 A). After 
treatment with irinotecan alone, 90% apoptotic cells and 1.3% necrotic cells were present. 
When exogenous methyl pyruvate was combined with irinotecan 90.7% of apoptotic cells with 
only 1.4% of necrotic cells were observed.  
On the other hand, when MDA-MB 231 cells were treated with exogenous methyl pyruvate 
alone for 48 hours, 9.1% died by apoptosis while  40% died by necrosis . Treatment with 
irinotecan alone, 15% apoptotic cells and 20% necrotic cells was present. Even upon the 
combined treatment, only 1.6% of apoptotic cells and 22.3% of necrotic cells were observed. 
It therefore appears exogenous methyl pyruvate can induced cell death regardless of the p53 
status since both cancer cells lines died albeit, with MDA-MB 231 less sufficiently .  
Moreover, introduction of exogenous methyl pyruvate protected MRC-5 normal lung fibroblast 
cells, as a decrease in apoptotic and necrotic cells were observed with an increase in live cells 
compared to treatment with 0.5 µM irinotecan alone (Figure 3.2 C). After 48 hours treatment 
of exogenous methyl pyruvate with irinotecan, only 6.4% of apoptotic cell was observed 
compared to irinotecan treatment alone, where 21% apoptotic cells were observed. Upon 
recovery from exogenous methyl pyruvate alone and combined with irinotecan compared to 
recovery from irinotecan alone, more live cells were observed   (Figure 3.2 D). When cells 
recover from the drugs, only 7.9% of apoptotic cells were observed compared to recovery from 
irinotecan alone, where 18% apoptotic cells were observed (Figure 3.2 D).  These results 
suggest that exogenous methyl pyruvate might provide protection to normal cells exposed to a 
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DNA damaging agent during treatment and recovery since apoptosis and necrosis were 
reduced.   
 
Figure 3.2 Introduction of exogenous methyl pyruvate protects normal MRC-5 cells from 
irinotecan induced cell death while promoting cancer cell death. Flow cytometer analysis with 
Annexin V and propidium iodide staining revealed percentage of cells undergoing apoptosis and 
necrosis when treated. A549 (A), MDA-MB 231 (B), and MRC-5 (C) were treated for 4 hours, 24 hours 
and 48 hours with irinotecan in the presence and absence of methyl pyruvate respectively. MRC5 cells 
(D) were treated for 4, 24, and 48 hours then DMEM was replaced with fresh DMEM-nutrient 
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supplemented medium and was allowed to grow for further 24 hours for recovery. The following 
symbols were used to represent each treatment; MP- methyl pyruvate, Ir- irinotecan, COT- irinotecan 
combined with methyl pyruvate treatment, and UN- untreated cells.  
 
The next objective was to determine the cell cycle distribution after treatment with exogenous 
methyl pyruvate alone, irinotecan alone and the combined treatment. This was necessary to 
determine the profile of cell cycle changes resulting from the previous treatments in two cancer 
cells and MRC-5 normal fibroblast.  Cellular DNA content of treated and untreated cells were 
quantitatively measured by staining with propidium iodide in order to assess changes at each 
phase of the cell cycle.     
Introduction of exogenous methyl pyruvate alone and with irinotecan resulted in a significant 
increase in cancer cells (A549 and MDA-MB 231) in the sub G0/G1 phase with most MRC-5 
normal cells arrested at the G0/G1 phase (Figure 3.3 C). The sub G0/G1 shift of cells was an 
indication of cell death taking place since this phase of the cell cycle is characterized by cells 
having less than 2n of DNA as oppose to the subsequent phase.  After 48 hours of treatment 
with exogenous methyl pyruvate combined with irinotecan, a significant increase in A549 cells 
was present in the sub G0/G1 phase (p = 0.00021) compared to all other treatments (Figure 3.3 
A).  However, treatment with methyl pyruvate alone and irinotecan alone, only 40 - 60% of 
cells accumulated in the sub G0/G1 phase. This implies that introduction of exogenous methyl 
pyruvate combined with irinotecan was more effective in killing A549 cells compared to all 
other treatments.   
Exogenous methyl pyruvate combined with irinotecan  was not as effective in killing MDA-
MB 231 cells, since a significant increase in cells in the S-phase (p = 0.0055) and G2/M phase 
(p = 0.00032) was observed, indicating cell growth (Figure 3.3 B). This corroborates findings 
from the previous section that the p53 status is important for cancer cell death to occur by the 
combined treatment. Irinotecan treatment alone also did not result in a notable amount of cell 
death as only 20% of cells were present in the sub G0/G1 phase (Figure 3.3 B). Interestingly, 
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treatment with exogenous methyl pyruvate alone resulted in a significant increase in MDA-
MB 231 cells in the sub G0/G1 phase (p = 0.00031) of the cell cycle, suggesting that 
introduction of exogenous methyl pyruvate is able to induce cell death independent of wild 
type p53.   
In MRC-5 cells, in contrast to cancer cells, introduction of exogenous methyl pyruvate resulted 
in a significant decrease in cells accumulating in the sub G0/G1 phase (p = 0.00319) with no 
significant increase of  cells in the G0/G1 phase (p = 0.29) compared to irinotecan treatment 
alone (Figure 3.3 C). This implies that introduction of methyl pyruvate inhibited irinotecan-
induced cell death, with most cells arresting in the G0/G1 phase. It is noteworthy that during 
recovery from exogenous methyl pyruvate  compared to recovery from irinotecan alone, a 
significant increase of cells in the S-phase (p = 0.000071) and G2/M checkpoint (p = 0.00050) 
was observed (Figure 3.3 D). These results suggest that introduction of exogenous methyl 
pyruvate protected normal MRC-5 cells from irinotecan-induced cell death by arresting most 
cells at the G0/G1 phase.  
In A549 lung cells, death increased when exogenous methyl pyruvate alone or with irinotecan 
was used, while the opposite was observed in MRC-5 normal lung fibroblast cells. These 
results therefore indicate that introduction of exogenous methyl pyruvate can selectively inhibit 
cancer cell proliferation while promoting proliferation in normal cells.  
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A. A549 lung cancer cells  
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B. MDA-MB 231 breast cancer cells 
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C. MRC-5 normal lung fibroblast cells  
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D. MRC-5 normal lung fibroblast cells (Recovery) 
 
 
Figure 3.3 Introduction of exogenous methyl pyruvate promote cell cycle progression in MRC-5 
normal cells : Cell cycle distribution of A549 (A), MDA-MB 231 (B), MRC-5 (C) and MRC-5 treated 
and recovered (D) cells treated with 2 mM methyl pyruvate in the presence and absence of 0.5 µM 
irinotecan for 4, 24 and 48 hours respectively. For all figures, data was acquired using the BD Accuri 
C6 flow cytometry. Bar graphs represent cell cycle analysis by flow cytometry in A549 (A), MDA-MB 
231 (B), MRC-5 (C), and MRC-5 upon recovery (D). Experimental data was from three independent 
experiments and were considered statistically significant when the p-value was ≤ 0.05. p-value ≤ 0.001 
B. Monchusi: PhD Thesis  
61 
 
(**) was considered statistical significant, p-value ≤ 0.05 (*) considered statistically significant and p-
value ≥ 0.05 (ns) was considered not to be statistically significant. The statistical analysis was done 
using the Graphpad software. A statistical summary, including the means and standard deviations of 
the cell cycle phases are presented in Table A1. The error bars reflect the standard error of the mean of 
biological replicates. The following symbols were used to represent each treatment; MP- methyl 
pyruvate, Ir- irinotecan, COT- cotreatment, and UN- untreated cells.  
 
3.3 Methyl pyruvate protects the normal fibroblast cell line by switching-off 
apoptotic pathways 
 p53 is often targeted by chemotherapeutic drugs and is known to be activated by irinotecan 
(Ntwasa, 2015). When activated by a DNA damaging agent, p53 initiates G0/G1 arrest of the 
cell cycle, activating downstream effector genes such as p21 (Sherr, 2000). p53 has also been 
shown to induce apoptosis by recruiting BCL-XL and BH3-domain containing proteins via the 
intrinsic or extrinsic cell death pathways (Haupt et al., 2003; Wu et al., 1997). The active 
metabolite of irinotecan, SN-38, was observed to significantly induce apoptosis by increasing 
the expression of p53, Bax, and caspase-9 while decreasing the anti-apoptotic gene, Bcl-xL, 
expression in human hepatocellular carcinoma cells after 24 hours of treatment (Takeba et al., 
2007).  
 
Also, p53 has been suggested to negatively regulate glycolysis at multiple points and to 
promote oxidative respiration by transcriptional control of the synthesis of Cytochrome c 
Oxidase 2 (SCO2) gene (Ma et al., 2007; Vousden and Ryan, 2009). Moreover, normal cells 
sense glucose availability by a p53-dependent pathway whereby the AMP-activated protein 
kinase phosphorylates p53 on serine 15 resulting in   cell cycle arrest at G1/S (Jones et al., 
2005). Presumably, MDM2 and RBBP6, which are known p53 negative regulators (Li et al., 
2007; Ntwasa, 2016) might also be involved in glucose metabolism.   
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The molecular pathways involved in response to treatment with exogenous methyl pyruvate 
combined with irinotecan were assessed by profiling gene expression using the reverse 
transcriptase polymerase chain reaction and Western blot analyses on A549, MDA-MB 231, 
and MRC-5 cells. Gene expression levels of p53, MDM2, p21, Bax, BID, caspase-9, and 
caspase-3 was monitored through RT-PCR analysis. Protein expression levels of p53, RBBP6 
and cytochrome c were monitored through Western blot analysis.   
Treatment with irinotecan alone caused a reduction in the p53 and p21 transcripts (Figure 3.4 
A) which correlates with the decrease in cell death (Figure 3.2 A) in A549 cells compared to 
exogenous methyl pyruvate alone and the combined treatment. In MDA-MB 231 cells, p53 
was upregulated (Figure 3.4 B) with no increase in cell death (Figure 3.2 B) after irinotecan 
treatment alone. In MRC-5 cells p53 and p21 transcripts were expressed at low levels (Figure 
3.4 C) which correlated with the minimal percentage cell death (Figure 3.2 C). Introduction of 
exogenous methyl pyruvate enhanced the p53/p21 axis (Figure 3.4 A) that correlated with cell 
death (Figure 3.2 A) in A549 while in MDA-MB 231 cells no correlation was seen. Even 
though p53 was upregulated after 48 hours of the combined treatment (Figure 3.4 B), no 
increase in cell death was observed in MDA-MB 231 cells (Figure 3.2 B). This was expected, 
as studies have shown that when p53 is mutated, it functions aberrantly. This suggest what was 
speculated in the previous sections that cotreatment - induced cell death is p53-dependent.  
Interestingly in MRC-5 cells the p53/p21 axis (Figure 3.4 C) was abrogated which correlated 
to cell survival (Figure 3.2 C).  
Both p21 and p53 were abolished upon recovery from exogenous methyl pyruvate and the 
combined treatment, suggesting the inhibition of p53 dependent apoptosis. It is noteworthy that 
a decrease in p53 transcript levels can be observed after treatment with exogenous methyl 
pyruvate alone (Figure 3.4 B), with an increase in necrotic cell death (Figure 3.2 B), suggesting 
that exogenous methyl pyruvate alone might also induce another cell death pathway that is 
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independent of the p53 pathway. Across the various treatments, MDM2 was not affected by 
changes in p53 expression in MDA-MB 231 cells, since the mutation is in the p53 binding 
domain.  
Little or no change was seen in the mitochondrial cell death genes (BID, BAX, Caspase-9 and 
Caspase-3) in both cancer cells after treatment with exogenous methyl pyruvate alone or when 
combined with irinotecan. However, after 24 hours treatment with exogenous methyl pyruvate 
alone and 4 hours of the combined treatment an increase in caspase-9 levels were observed in 
A549 cells (Figure 3.4 A). This suggests that the mitochondrial cell death pathway was 
induced, as caspase-9 is required for intrinsic apoptosis. The mitochondrial cell death genes 
were expressed at low levels after introduction of methyl pyruvate and seemed to be abolished 
when the drugs were removed in MRC-5 cells, suggesting inhibition of intrinsic apoptosis 
(Figure 3.4 C and D).  
Induction of intrinsic cell death was further evident by the upregulation of cytochrome c in 
A549 cancer cells. While the inhibition of the intrinsic pathway by the deregulation of 
cytochrome c in MRC-5 normal lung fibroblast cells after treatment exogenous methyl 
pyruvate combined with irinotecan (Figure 3.4 E and G). This suggests that methyl pyruvate 
protected MRC-5 cells from irinotecan-induced cell death while promoting apoptosis in A549 
cancer cells. Introduction of exogenous methyl pyruvate downregulated cytochrome c protein 
in MDA-MB 231 cells with mutant p53 (Figure 3.4 F), where death was by necrosis (Figure 
3.2 B).  RBBP6 isoform 1 was upregulated in both cancer cells following treatment with 
exogenous methyl pyruvate and when combined with irinotecan. Moreover, this was 
accompanied by downregulation of p53 and increased cell death in A549 cells (Figure 3.4 E), 
indicating that RBBP6 might play a pro-apoptotic role during metabolic reprogramming.  In 
MDA-MB 231 cells, the presence of high levels of RBBP6 isoform 1 (Figure 3.4 F) suggests 
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that p53 was downregulated as this was followed by necrotic death (Figure 3.2 B) which is 
independent of p53. 
In MRC-5 fibroblasts, contrast to cancer cells, the appearance of a second RBBP6 isoform, 
isoform 3, was observed (Figure 3.4 G and H).  Expression of RBBP6 isoforms 1 and 3 seemed 
to have an inverse relationship across various treatments, even after recovery. RBBP6 isoform 
1 was upregulated after 24 hours of treatment with exogenous methyl pyruvate alone and when 
combined with irinotecan, in contrast to isoform 3 which was downregulated. This indicates 
cell proliferation since RBBP6 isoform 1 is known to play an anti-apoptotic role (Ntwasa, 
2016) while RBBP6 isoform 3 is a known pro-apoptotic factor (Mbita et al., 2012). However, 
RBBP6 isoform 1 became downregulated after recovery from the combined treatment, with an 
upregulation of RBBP6 isoform 3 (Figure 3.4 H), indicating G0/G1 arrest of MRC-5 cells 
(Figure 3.3 D)  
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Figure 3.4 Introduction of exogenous methyl pyruvate deregulates apoptotic pathways in MRC-
5 normal cells: (A) RT-PCR illustrating changes in gene expression of p53, MDM2, p21: p53 
pathway, BID, Bax, caspase-9, caspase 3: Intrinsic apoptotic cell death pathway during treatment 
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with methyl pyruvate in the presence and absence of the DNA damaging agent, irinotecan. The 
housekeeping gene, GAPDH, was used as the loading control. The band intensities were indicative of 
genes being upregulated or downregulated as a result of the various treatments. For each treatment, 
identical units of template were used. (B) Western Blot analysis illustrating changes in protein 
expression of p53, RBBP6 and cytochrome c in A549, MDA-MB 231, and MRC5  cells upon treatment 
with 2 mM methyl pyruvate in the presence and absence of irinotecan for 4, 24 and 48 hours.While 
MRC5 (Recovery) were treated for 4, 24, and 48 hours then DMEM was replaced with fresh DMEM-
nutrient supplemented medium and was allowed to grow for a further 24 hours for recovery. β-actin 
was used as the loading control to assess whether protein was loaded in each well. 
 
3.4 Methyl pyruvate promotes cell death in cancer cell lines but survival in 
the normal lung fibroblast cell line  
From the RT-PCR and Western blot analyses, the introduction of exogenous methyl pyruvate 
induced cell death mainly through the mitochondrial cell death pathway and p53 - pathway in 
A549 lung cancer cells. In MDA-MB 231 death was through another caspase-independent and 
p53-independent pathways. Furthermore, introduction of exogenous methyl pyruvate promoted 
the survival of MRC-5 normal lung fibroblast cells by switching off the p53-pathway and 
mitochondrial cell death pathway. It was pertinent to identify which other biological pathways 
might be affected by the combined treatment (exogenous methyl pyruvate with irinotecan).  
 A focused pathway study was conducted using the Human Cancer PathwayFinderTM RT2 
ProfilerTM PCR Array (PAHS-O33ZF-12) in order to profile 84 cancer-related genes. This 
microarray includes 84 genes representative of 9 different biological pathways genes involved 
in tumourigenesis. The differences in gene expression between A549 (untreated) and A549 
(co-treated) cells and between MRC-5 (untreated) and MRC-5 (co-treated) cells after 48 hours 
cotreatment were profiled. The data were analysed by QIAGEN data analysis software, 
PANTHER (Protein Analysis Through Evolutionary Relationships), Genemania Cytoscape 
and REACTOME.  
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In A549 cells, 25 genes were upregulated while in MRC-5 cells 20 genes were upregulated 
(Table 2). Moreover, 18 genes were downregulated in A549 (Table 3), with only one gene 
downregulated in MRC-5 cells, indicating that the drugs had an opposite effect on the two cell 
lines.  
From the Venn diagram, 17 upregulated genes were unique to A549 cells compared to MRC-
5 (Figure 3.5), with most mediating apoptosis, DNA damage and repair, and epithelia-to-
mesenchymal transition pathways (Table 2). On the other hand, in MRC-5 cell, 13 upregulated 
genes were unique (Figure 3.5) and most were responsible in mediating angiogenesis, 
epithelial-to-mesenchymal transition and cell senescence pathways (Table 2), indicating cell 
growth. Furthermore, 18 downregulated genes were unique to A549 cells (Figure 3.5), with 
most mediating cell cycle and angiogenesis pathways (Table 3), suggesting disruption and 
inhibition of cell cycle progression and cell growth.  
 
 
Figure 3.5 Genes upregulated and downregulated between MRC-5 and A549 cells after treatment 
with the drug combination: Venn diagram depicting differentially expressed genes between A549 
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lung cancer cells and MRC-5 normal lung fibroblast cells obtained using QIAGEN data analysis 
software. The central portion indicates unchanged gene expression.  
Table 2: Genes upregulated after treatment with exogenous methyl pyruvate combined with 
irinotecan in A549 and MRC-5 cells  
  Upregulated  genes  
 
 
Pathways  A549  Fold 
Regulation 
MRC-5 Fold 
Regulation 
References  
Apoptosis CASP7 
CFLAR 
BIRC3 
-- 
3.23 
3.17 
7.59 
-- 
-- 
-- 
FASLG 
 
 
 
 
9.61 
Lamkanfi 
and 
Kanneganti, 
2010; 
Wajant, 
2004; 
Wajant et 
al., 2003 
Angiogenesis ANGPT2 
VEGFC 
-- 
-- 
-- 
-- 
4.48 
3.69 
-- 
-- 
TEK 
(TIE2) 
SERPINF1 
ANGPT1 
PGF 
 
 
6.08 
 
3.67 
3.49 
3.02 
Carmeliet 
and Jain, 
2000 
Cell cycle CCND2 2.66 CCND2 3.49 
 
Dasika et al., 
1999 
 
DNA damage 
and repair 
DDIT3 
PPP1R15A 
ERCC5 
POLB 
DDB2 
-- 
4.80 
3.08 
2.16 
2.10 
2.00 
-- 
-- 
-- 
-- 
-- 
GADD45G 
 
 
 
 
 
9.61 
Khanna and 
Jackson, 
2001; Dasika 
et al., 1999 
Epithelial-to-
mesenchymal 
transition 
KRT14 
SNAI1 
SNAI2 
SNAI3 
-- 
-- 
12.58 
8.24 
3.08 
2.26 
KRT14 
SNAI1 
-- 
SNAI3 
GSC 
SOX10 
9.61 
2.63 
 
3.26 
9.61 
9.61 
Huber et al., 
2005; Yang 
and 
Weinberg, 
2008 
Hypoxia CA9 
ARNT 
-- 
3.15 
2.12 
CA9 
-- 
HMOX1 
EPO 
2.54 
 
2.01 
11.66 
Buffa et al., 
2010; Fardin 
et al., 2010; 
Yoon et al., 
2001 
Metabolism ACSL4 
 
5.99 --  Tennant et 
al., 2009; 
Moreno-
Sanchez et 
al., 2009 
Telomeres and 
telomerase  
TEP1 
TNKS2 
TERF2IP 
TINF2 
3.64 
2.98 
2.55 
2.54 
TEP1 
-- 
-- 
-- 
2.72 Martinez and 
Blasco, 
2010; Cohen 
et al., 2007 
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Cell 
senescence  
TBX2 
BMI 
-- 
-- 
3.10 
2.02 
TBX2 
-- 
IGFBP5 
SERPINB2 
4.51 
 
5.37 
2.26 
Reddel, 
2010; Othani 
et al., 2009 
 
Table 3: Table 10: Genes upregulated after treatment with exogenous methyl pyruvate 
combined with irinotecan in A549 and MRC-5 cells  
  Downregulated   genes  
 
 
Pathways  A549  Fold Regulation MRC-5 Fold 
Regulation 
References  
Apoptosis --  --  
 
 
 
 
Angiogenesis FLT1 
ANGPT1 
SERPINF1 
-15.21 
-4.13 
-2.18 
-- 
-- 
-- 
 
 
 
Carmeliet 
and Jain, 
2000 
Cell cycle CDC20 
MKI67 
MCM2 
STMN1 
AURKA 
CCND3 
SKP2 
-112.74 
-38.77 
-4.40 
-4.10 
-2.80 
-2.44 
-2.29 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
 Dasika et 
al., 1999 
DNA damage 
and repair 
--  --  
 
 
 
 
 
 
Epithelial-to-
mesenchymal 
transition 
FOXC2 - 2.84 --  Huber et al., 
2005; Yang 
and 
Weinberg, 
2008 
Hypoxia HMOX1 
 
-6.22 --  Buffa et al., 
2010; 
Fardin et al., 
2010; Yoon 
et al., 2001 
Metabolism G6PD 
COX5A 
 
-4.81 
-2.67 
  Tennant et 
al., 2009; 
Moreno-
Sanchez et 
al., 2009 
Telomeres and 
telomerase  
-- 
PINX1 
DKC1 
 
-3.15 
-2.63 
TERF1 
-- 
-- 
- 2.40 Martinez 
and Blasco, 
2010; 
Cohen et al., 
2007 
Cell 
senescence  
ETS2 -2.32 --  
 
Reddel, 
2010; 
Othani et 
al., 2009 
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PANTHER was used to group the unique genes obtained between A549 and MRC-5 cells into 
their corresponding biological pathways. Unique DEGs between A549 and MRC-5 were 
uploaded into PANTHER. Genes from the query list were grouped into pathways based on 
their molecular and biological functions. PANTHER classification system along with other 
ontology tools such as Gene ontology, and the Hidden Markov statistical model, were used to 
assign genes to specific pathways.  
Approximately 50% of the genes upregulated in A549 fibroblasts mediate apoptosis (Figure 
3.6 A), while of the 50% downregulated mediated cell cycle progression (Figure 3.6 B). This 
indicates what was suggested before (Table 2 and Table 3) that the drugs combined disrupted 
cell cycle progression and induced cell death. In contrast to A549 cells, those upregulated in 
the MRC-5 lung fibroblasts promote cell growth (40%), and cell survival (20%) (Figure 3.6 
C). This suggests what was speculated before that exogenous methyl pyruvate protected MRC-
5 cells from irinotecan-induced cell death. Furthermore, the only gene (TERF1) downregulated 
in MRC-5 cells had no hit in PANTHER pathways.  
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Figure 3.6 Introduction of exogenous methyl pyruvate protects normal MRC-5 cells by 
upregulating cell growth and survival pathways while inducing cell death in A549 cells by 
upregulating apoptotic pathways:  Using PANTHER the differentially expressed genes were further 
analysed to reveal biological pathways that were affected when the A549 and MRC-5 cells are treated 
with irinotecan and methyl pyruvate. Uniquely expressed genes were used as input into PANTHER to 
identify perturbed biological pathways. The percentage of up or downregulated genes are an indication 
of the percentage of gene hit against total number of pathway hits. In MCR-5 cells, the drug combination 
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upregulated anti-apoptotic and anti-angiogenic factors (C) while in A549 cells pro-apoptotic and pro-
angiogenic factors were induced (A and B).  
 
The next step was to group the unique genes into their molecular functional classes. This was 
pertinent as this will aid in identifying genes that may encode for proteins involved in a 
complex coordinated activity such as DNA replication or RNA splicing. GeneMANIA 
cytoscape plugin was used for functional interaction analyses. Genes that were unique in both 
MRC-5 and A549 cells, were used as input (query list) into the GeneMANIA cytoscape plugin. 
In order to show the relationship among genes from the data set, GeneMANIA extends the 
query gene list with genes that are functionally similar. Interactions were considered 
statistically significant when q < 0.05. The q-values were estimated by the in-built Benjamini-
Hochberg procedure. 
It was found that treatment with exogenous methyl pyruvate combined with irinotecan induced 
apoptosis and anti-angiogenic factors in A549 lung cancer cells and pro-angiogenic and pro-
survival factors in the MRC-5 fibroblasts (Figure 3.7). In A549 cells pathways such as the 
intrinsic apoptotic signalling pathway (q = 2.9e-05) and the telomere maintenance via 
telomerase (q = 3.2e-12) were significantly upregulated (Figure 3.7 A) while the angiogenesis 
(q = 0.021), DNA polymerase activity (q = 0.021), mitosis (q = 0.022) were significantly 
downregulated (Figure 3.7 B). In MRC-5 cells, in contrast to A549 cell, pathways such as 
angiogenesis (q = 1.3e-08) and positive regulation of cell adhesion (q= 0.0037) were 
significantly upregulated (Figure 3.7 C). This can be supported by other findings in this study 
in which cell death was observed in A549 cells and cell growth in MRC-5 with the combined 
treatment (exogenous methyl pyruvate and irinotecan)  (Figures 3.1 and 3.2 A, C, and D). These 
results suggests that introduction of exogenous methyl pyruvate induced cell death in A549 
cells while promoting cell proliferation in MRC-5 normal cells.  
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This is further evident  by the upregulation of  ANGPT1  in the MRC-5 fibroblasts, while  its 
antagonist ANGPT2 was upregulated in the A549 cancer  cell line indicating that the combined 
treatment had opposite effects in these cell lines (Figure 3.7 A and C). The drug-induced pro-
angiogenic pathways in MRC-5 fibroblasts are mediated by known pro-angiogenic factors and 
by molecules classified as components of blood coagulation and plasminogen activating 
cascades, including erythropoietin/thrombopoietin (EPO) (Figure 3.7 C) 
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Figure 3.7 Introduction of exogenous methyl pyruvate protects MRC-5 cells by upregulating 
angiogenesis and cell adhesion processes: The GeneMANIA module in Cytoscape (version 3.3.0) was 
applied   to construct interaction networks in each cell line. The Networks represent upregulated and 
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downregulated gene sets after treatment with both drugs (irinotecan and methyl pyruvate) for 48 hours. 
Genes in the submitted query list are indicated as circular nodes while those predicted to be related are 
displayed as diamond nodes (<>). Pathway categories received a score weight when the pathways data 
sets in GeneMANIA link to members of the query list. The edges (coloured lines) that connect 
neighbouring genes are depicted as follows: medium purple: Co-expression, medium turquoise: 
pathway; brown: physical interaction; blue: co-localization; khaki: shared protein domains. 
Interactions were considered statistically significant when q < 0.05.  
 
Using the REACTOME pathway overview (Figure 3.8) and REACTOME pathway diagram 
analysis (Figure B2) in A549 and MRC-5 cells after introduction of exogenous methyl pyruvate 
combined with irinotecan, similar results were observed. Pathways were considered 
statistically enriched when the p < 0.05. In A549 lung fibroblast cancer cells the combined 
treatment significantly upregulated pathways such as the DNA repair (p = 0.002), programmed 
cell death (p = 0.011), and VEGF signaling (p = 0.032) (Figure 3.8 A) while down regulating 
DNA strand elongation (p = 000079) and cell cycle pathways (p = 0.001), suggesting disruption 
and inhibition of DNA replication and cell growth. This is further supported by the disruption 
of the DNA replication fork and the upregulation of caspase-7 in the intrinsic apoptotic 
pathway through in-depth REACTOME analysis (Figure 2B). Furthermore, in MRC-5 cells in 
contrast to A549, the drug combination significantly upregulated pathways such as signaling 
by VEGF (P = 0.005), Tie2 signaling (p = 0.006), hemostasis (p = 0.051) (Figure 3.8 C), 
indicating cell survival and cell growth. 
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Figure 3.8 Exogenous methyl pyruvate protects MRC-5 cells from irinotecan-induced cell death 
by upregulating Developmental biology, signal transduction and homeostasis pathways: 
REACTOME analysis was conducted using query lists of differentially expressed genes in A549 and 
MRC-5 cells. Pathways were considered enriched when a significant number of the query list genes 
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were part of a particular pathway against the overall pathway genes. Each pathway was considered 
statistically enriched when the p < 0.05. REACTOME produced maps of 24 pathways, with upregulated 
and downregulated pathways highlighted (in red) indicating those induced in (A-B) A549   and (C) 
MRC-5 cells. The central node of each radial representation corresponds with the uppermost level of 
the hierarchy (such as programmed cell death) while the concentric rings of nodes around the central 
node represents successive events of the hierarchy (such as intrinsic/extrinsic apoptotic signalling 
pathways).   
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Chapter 4: Discussion  
              
4.0 Introduction 
This study shows that the reversal of the Warburg effect by exogenous methyl pyruvate is 
sufficient to kill cancer cells and protect normal cells from the toxicity of chemotherapeutic 
agents such as irinotecan.  
The exogenous methyl pyruvate, combined with irinotecan, rescued normal MRC-5 lung 
fibroblasts from irinotecan-induced cell death as an increase in live cells was observed, with 
most cells accumulating at the G0/G1 phase, S-phase, and the G2/M phase, indicating cell cycle 
progression. In contrast the same treatment induced apoptosis in the lung cancer cell line A549 
with most cells accumulating at the sub G0/G1 phase. In MDA-MB 231 cells, treatment with 
exogenous methyl pyruvate alone induced necrosis and apoptosis with most cells accumulating 
at the G0/G1 phase and at the sub G0/G1 phase indicating cell cycle arrest and cell death.  
It was also observed that the p53/p21 axis was deregulated after introduction of exogenous 
methyl pyruvate with a significant decrease in cell death. In contrast to MRC-5 cells, the 
p53/p21 axis was enhanced in A549 cells followed by a significant increase in cell death. 
However, in MDA-MB 231 cells, death was through another p53-independent pathway 
following exposure as an increase in necrotic cells was observed.  
Through pathway focussed gene expression profiling, exogenous methyl pyruvate in 
combination with irinotecan promoted cell proliferation by upregulating angiogenic and 
survival factors in MRC-5 cells, while in A549 cells, it induced cell death by upregulating pro-
apoptotic and anti--angiogenic factors. These findings are explained in detail in the following 
sections.  
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4.1 Methyl pyruvate protects MRC-5 fibroblasts from irinotecan induced 
cell death 
During chemotherapy, both cancer and normal cells are exposed to genotoxic stress. The major 
shortcoming of chemotherapeutic drugs is that they possess little discrimination between the 
rapidly dividing cancer cells and normal cells leading to severe side effects. These drugs have 
been suggested to negatively affect the gastrointestinal tract, hair bulbs, reproductive organs, 
the haematopeotic system, and the lymphatic tissue (Lorusso et al., 2010). Exploring the 
phenotypic difference between normal and cancer cells may provide a strategy to selectively 
target cancer cells. The glycolytic phenotype of cancer cells as a chemotherapeutic target was 
explored by enhancing OXPHOS. The xCELLigence technology, Annexin-V and PI-staining 
assays were used to monitor cell proliferation and measuring cell death, respectively. 
Using the xCELLigence technology, 2 mM exogenous methyl pyruvate alone and in 
combination with 0.5 µM irinotecan killed both cancers (A549 and MDA-MB 231) while 
promoting survival of MRC-5 normal cells. This study corroborates those of others, which 
observed the toxicity of irinotecan to normal and cancer cells (Garcia-Carbonero and Supko, 
2002). The promotion of survival when MRC-5 cells were treated with exogenous methyl 
pyruvate in the presence of irinotecan suggests its role in protecting normal cells from toxicity. 
These findings coincide with a previous study that showed protection of normal blood cells but 
not leukaemic cells using ethyl pyruvate (Hollenbach et al., 2008). In another study they found 
that 1 mM ethyl pyruvate increased survival of C57BL/6NHsd mice undergoing total body 
irradiation treatment (9.75 Gy TBI) (Epperly et al., 2007).  
Using the Annexin-V and PI-staining, this study further observed the discrimination between 
cancer and normal cells by introduction of exogenous methyl pyruvate. An increase in cell 
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death in A549 and MDA-MB 231 cells while, in MRC-5 cells an increased in live cells was 
observed over time. This coincides with a study that showed cancer cells (MCF-7, A549, and 
M059k) were killed without harming SAEC normal cells after treatment with dicloroacetate 
(Bonnet et al., 2007). Dicloroacetate is a known inhibitor of the pyruvate dehydrogenase kinase 
(PDK) enzyme. PDK leads to the activation of pyruvate dehydrogenase (PDH) which is 
involved in convertsion of pyruvate to acetyl CoA before entering the TCA cycle (Whitehouse 
and Randle, 1973).  
It is noteworthy, that this study shows that treatment with exogenous methyl pyruvate alone 
killed the mutant p53 MDA-MB 231 cells as compared to irinotecan treatment alone. This was 
interesting since MDA-MB 231 cells are known to be resistant to most chemotherapeutic drugs 
(Hussien and Brooks, 2011). It has been observed that functional p53 is important in sensitizing 
cancer cells to chemotherapeutic drugs (Zhang et al., 1998; Zhang et al., 1999; Lowe et al., 
1993). Interestingly, exogenous methyl pyruvate induced necrotic cell death in MDA-MB 231 
cells probably through the accumulation of mitochondrial-derived ROS. It has been speculated 
that programmed necrotic cell death occurs due to an increase in mitochondrial-derived ROS 
and calcium (Festjens et al., 2006). Induction of necrosis has also been observed previously, 
upon treatment with PRIMA-1 combined with flavopridipol in leukemia cells carrying mutant 
p53 (Cory et al., 2006). 
These results show that exogenous methyl pyruvate protects normal cells from the toxicity of 
chemotherapeutic agents and is a promising adjunctive in this regard.  
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4.2 Exogenous methyl pyruvate promotes cell cycle progression in normal 
cells but cell death in cancer cells 
Using PI-staining, it was observed that exogenous methyl pyruvate alone and in combination 
with irinotecan, promotes cell cycle progression in normal cells as a large percentage of cells 
accumulated at the G0/G1 phase. This suggests that introduction of exogenous methyl pyruvate 
protects MRC-5 cells from irinotecan’s toxicity. The protective effect of exogenous methyl 
pyruvate is further supported by deregulation of the p53/p21 axis, suggesting inhibition of cell 
death. This coincides with a previous study, that showed that cell viability increased in three 
human normal fibroblast cells (WI38, MRC-5, HFL1) after exposure to RY4 peptide combined 
with DCA, an enhancer of endogenous pyruvate (Wu et al., 2014).  
In contrast to what was observed in normal MRC-5 cells, the introduction of exogenous methyl 
pyruvate to both cancer cell lines (A549 and MDA-MB 231) accelerated cell death as an 
increased in cells in the sub G0/G1 phase was observed. Exogenous methyl pyruvate sensitised 
a 90.7% of A549 cells to irinotecan. This is supported by the enhanced expression levels of 
p53 and p21 by RT-PCR which implies the induction of apoptosis. This suggests that the 
presence of functional p53 in these cells increased their sensitivity to the combined treatment. 
In another study, cells with wild type p53 were found to be more sensitive to a variety of DNA 
damaging agents (cisplatin, nitrogen mustard, etoposide, and γ – irradiation) compared to cells 
with mutant p53 (Piovesan et al., 1998). This is because many chemotherapeutic agents are 
known to target the p53-pathway to induce cancer cell death.  
In the present study, cell death in MDA-MB 231cells, which are p53 mutant, was observed 
although it appeared to be less efficient compared to in A549 cells suggesting that exogenous 
methyl pyruvate can induce another cell death mechanism that is p53-independent. 
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Experiments using RT-PCR further supported this hypothesis by showing downregulation of 
the p53/p21 axis in MDA-MB 231.  
 
From these results, introduction of exogenous pyruvate can be explored in chemotherapy as an 
adjunctive as it supports normal MRC-5 cell survival with cells accumulating at the G0/G1 
phase while promoting cancer cell death.  
 
4.3 Methyl pyruvate deregulates apoptotic pathways 
The expression profile of genes involved in the p53 pathway and the intrinsic-mitochondrial 
apoptosis pathway was investigated to elucidate the molecular basis for the observed 
phenotypes after treatment with irinotecan combined with methyl pyruvate. RT-PCR and 
Western blot analyses were used to profile expression of the p53-pathway: p53, MDM2, and 
p21 and the mitochondrial cell death pathway; BAX, BID, caspase3, caspase-9, cytochrome c, 
and RBBP6.  
It was observed that introduction of exogenous methyl pyruvate protects MRC-5 cells from 
irinotecan-induced cell death by switching off apoptotic pathways, since p53 and p21 were 
downregulated. p21 is a known pro-apoptotic protein that is transactivated by p53. Genes such 
as BAX, BID, caspase-3, and caspase-9 were depleted after exogenous methyl pyruvate was 
added, suggesting inhibition of intrinsic apoptosis. This is further supported by the 
downregulation of cytochrome c protein, as cytochrome c must be released from the 
mitochondrial membrane, and form the apoptosome (with Apaf-1 and procaspase-9) to activate 
caspase-9. Cytochrome c initiates the intrinsic cell death pathway by activating downstream 
cascade of caspases leading to the induction of apoptosis (Crompton, 2000; Haupt et al., 2003). 
This suggests that introduction of exogenous methyl pyruvate provides protection to normal 
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MRC-5 cells during chemotherapy (irinotecan treatment) by deregulating the apoptotic 
machinery.   
However, in A549 cancer cells (wild type p53) the introduction of exogenous methyl pyruvate 
induced intrinsic cell death by enhancing the p53/p21 axis and mitochondrial apoptotic 
pathway as upregulation of p53, p21, and caspase-9 transcripts was observed. Caspase-9 is a 
known initiator caspase that cleaves and activates the executioner caspases such as caspase-3.  
It has been shown that Apaf-1 and/or caspase-9 are required for p53-dependent apoptosis to be 
induced (Soengas et al., 1999; Schuler et al., 2000).  The induction of the intrinsic pathway is 
further supported by the upregulation of cytochrome c protein. The upregulation of cytochrome 
C suggests that exogenous methyl pyruvate induced a p53-dependent, intrinsic cell death. The 
activation of the mitochondrial function corroborates with another study, wherein A549 cells 
were exposed to exogenous methyl pyruvate combined with x-ray causing the mitochondrial 
energy metabolism pathway to be induced (Nishida et al., 2014).    
These results indicate that the introduction of exogenous methyl pyruvate promotes cancer cell 
death by inducing the p53/21 axis and mitochondrial cell death pathways while increasing 
survival in normal MRC-5 cells by switching off these pathways.  
4.4 Exogenous methyl pyruvate can also induce another p53-independent 
and caspase-independent cell death  
Introduction of exogenous methyl pyruvate induced a p53-independent and caspase-
independent cell death in MDA-MB 231 cells, as p53, p21, Bax, and caspase-9 were 
downregulated as shown by RT-PCR analysis. This is also evident by the downregulation of 
cytochrome c protein shown by Western blot analysis suggesting the inhibition of intrinsic cell 
death pathway. These findings corroborate a study by Dorsam et al., (2015), showing that 
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exposure to lipoic acid, a cofactor of the pyruvate dehydrogenase complex, also induced a 
caspase-independent cell death in human colon cancer cells (HCT116: p53 null cells).  
Even though p53 and p21 were upregulated after treatment with irinotecan, cell death was 
minimal compared to treatment with exogenous methyl pyruvate.  This finding corroborates 
what was reported by Takimoto et al., (2002); where CP31398 (a, styrylquinazoline agent) was 
shown to upregulate p53 target genes such as p21. However, their expression did not correlate 
with the induction of cell cycle arrest or apoptosis in colon, breast, lung, ovarian and 
osteosarcoma cancer cells. The observation from the current study supports findings by other 
studies, that cancer cells with mutant p53 are less sensitive to chemotherapeutic agents. 
Another study by Nabeya et al., (1995), has shown that gastric/esophageal cancer cells 
expressing mutant p53 were more resistant to chemotherapeutic agents (5-fluorouracil, 
mitomycin C, and cis-dicholorodiammin-eplatinum (II)) despite the increase in mutant p53 
expression levels. These results indicate that introduction of exogenous methyl pyruvate can 
induce cancer cell death through p53-independent and caspase-independent pathways in cancer 
cells with mutant p53. 
4.5 The role of RBBP6 during metabolic reprogramming 
The role of RBBP6 in response to metabolic reprogramming in normal and cancer cells was 
investigated. Expression of RBBP6 was assessed before and after treatment with exogenous 
methyl pyruvate and irinotecan by Western blot analysis. Retinoblastoma binding protein 6 
(RBBP6) is essential for chaperone-mediated ubiquitination of p53. RBPP6 targets p53 for 
degradation by enhancing the activity of MDM2, through its RING finger-like domain (Chen 
et al., 2013). 
After introduction of exogenous methyl pyruvate p53 levels became depleted while an increase 
in RBBP6 isoform 1 protein expression was observed in A549 cell line. This may suggest a 
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negative feedback loop between RBBP6 and p53. These findings corroborate a previous study 
that showed knockdown of RBBP6 led to an upregulation of p53 in mice resulting in embryonic 
lethality (Li et al., 2007). Interestingly, upregulation of RBBP6 isofrom 1 in both cancer cell 
lines (A549 and MDA-MB 231) was observed after introduction of exogenous methyl 
pyruvate, with an increase in cell death shown in Figure 3.3 A and B. This suggest that RBBP6 
isofrom 1 might play a pro-apoptotic role during metabolic reprogramming. This is also evident 
by the significant shift of A549 and MDA-MB 231 cell lines into the sub G0/G1 phase, 
indicating cell death. However, the exact mechanism by which RBBP6 isofrom 1 facilitates 
cell death during metabolic reprogramming is not clear. This is the first study to propose a role 
of RBBP6 isoform 1 during metabolic reprograming in cancer cells. To date RBBP6 isoform 
1, a negative regulator of p53, is known to facilitate cell proliferation (Moumen et al., 2007).  
 In MRC-5 normal cells, introduction of exogenous methyl pyruvate resulted in the differential 
expression of two RBBP6 isoforms (isoform 1 and isoform 3). Isoform 1 was enhanced while 
isoform 3 expression was reduced after 24 hours of treatment with exogenous methyl pyruvate 
and combination treatment. This may suggests that RBBP6 isoform 1 and 3 have an inverse 
relationship. These results corroborates with others that RBBP6 isoform 3 and isoform 1 are 
inversely regulated during differentiation of C2C12 cells (Ji and Yian, 2009).  RBBP6 isoform 
1 upregulation and isoform 3 downregulation thus indicate growth. The upregulation of isoform 
1 after introduction of exogenous methyl pyruvate indicates cell growth which is evident in 
Figure 3 C. Introduction of exogenous methyl pyruvate resulted in cell cycle progression, with 
most MRC-5 cells accumulating at the G0/G1 phase. These results suggest that the introduction 
of exogenous methyl pyruvate promotes cell proliferation by modulating the expression of 
RBBP6 isoform 1 and isoform 3 in MRC-5 fibroblast.   
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4.6 Exogenous methyl pyruvate upregulates pro-angiogenic and survival 
pathways in MRC-5 normal cells and pro-apoptotic pathways in A549 cells  
The molecular bases of the observed phenotypes in cancer and normal cells was investigated 
after the introduction of exogenous methyl pyruvate to irinotecan-tretaed cells. For comparison 
purposes, A549 lung cancer cells and MRC-5 normal lung fibroblast cell line were used as they 
are both lung-derivedcell lines. The Human Cancer PathwayFinderTM RT2 ProfilerTM PCR 
Array, (PAHS-O33ZF-12) was used to profile 84 cancer-related genes. Furthermore, 
PANTHER, GeneMANIA and REACTOME were used for pathway analysis. It was observed 
that exogenous methyl pyruvate promoted cell survival in the normal fibroblast cell line and 
cell death in the cancer cell line.  
Unique genes such as TEK, ANGPT1, GSC, GADD45G, and EPO that were upregulated in 
MRC-5 cells were part of pro-angiogenic, plasminogen-activating cascade, and blood 
coagulation factors which promoted cell proliferation and survival. Angiopoietin 1 (ANGPT1) 
and its corresponding receptor, TEK/TIE2 are known to control vascular morphogenesis and 
homeostasis (Augustin et al., 2009; Maisonpierre et al., 1997). It has been shown that systemic 
administration of ANGPT1 protein (COMP-angiopoietin-1) protects the kidney from diabetic 
microvascular damage in mice (Lee et al., 2007). Cell cycle progression previously shown in 
Figure 3.3 C and D is further suggested by the upregulation of the Growth arrest and DNA-
damage-inducible 45 gene (GADD45) which interacts with the Cdk1/CyclinB1 complex (Na 
et al., 2010). GeneMANIA also showed the upregulation of molecules such as Goosecoid 
(GSC) that play a role in enhancing cell adhesion. GSC, is known to control glucose 
metabolism by targeting genes that are active in the pancreas, liver, and adipose tissue 
(Friedman and Kaestner, 2006). 
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Erythropoietin (EPO) was also observed to be upregulated when normal cells were treated with 
exogenous methyl pyruvate combined with irinotecan. Erythropoietin (EPO), a glycoprotein 
hormone is essential in the regulation of the red blood cell mass, participating in negative 
feedback control from a renal oxygen sensor to the erythroid system, resulting in an increase 
in hemoglobin levels (Lacombe et al., 1988). Studies have speculated that nephrotoxicity 
lowers EPO secretion and through this mechanism, contributes to anaemia observed after 
therapy with several chemotherapeutic agents (Fjornes et al., 1998). It has been shown that 
cisplatin-associated anaemia was persistent with EPO deficiency state, which resulted from 
cisplatin-induced renal tubular damage (Wood and Hrushesky, 1995). Furthermore, they found 
that these effects could be prevented or treated by EPO replacement. Thus an upregulation of 
EPO may lower toxicity associated with chemotherapeutic agents such as nephrotoxicity.  
In A549 cells, most uniquely upregulated and downregulated genes was part of pro-apoptotic 
and pro-angiogenic factors.  Caspase-7 a known proapoptotic gene were upregulated. Caspase-
7, is known to induce apoptosis, which entails cellular morphological changes such as 
phosphatidylserine exposure, nuclear condensation, and genomic DNA fragmentation 
(Lamkanfi and Kanneganti, 2010). Its upregulation indicates an increase in apoptosis. 
Furthermore, caspase-7 along with caspase-3 shows specificity towards multiple substrates, 
including XIAP, BID, and gelsolin (Walsh et al., 2008) indicating the activation of the intrinsic 
mitochondrial cell death pathway in A549 cells after introduction of exogenous methyl 
pyruvate. Additionally, in this study, the downregulation of cell cycle genes such as CDC20 
and STMN1 was observed to be consistent with the inhibition of cell proliferation in A549 
cells. The cell division cycle 20 homologue (CDC20) plays a key role in activating the anaphase 
promoting complex (APC/C) thereby leading to mitotic progression (Hoeller et al., 2006). 
Stathmin 1/oncoprotein-18 (STMN1), the microtubule-destabilizing protein, is essential during 
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mitosis, to positively influence cell cycle progression (Rana et al., 2008; Belletti and 
Baldassarre, 2011).  
REACTOME pathway analysis further showed that in A549 cancer cells, DNA damage and 
repair genes such as DNA damage-inducible transcript 3 (DDIT3) and DNA damage-binding 
protein 2 (DDB2) were upregulated after the drug combination and was consistent with cell 
death. Overexpression of DDIT3 induces cell cycle arrest and apoptosis in certain cancers 
(Barone et al., 1994; Zinszner et al., 1998). DDIT3 transcription, mRNA stability, and 
translation are induced in response to DNA damage, ER stress, hypoxia, and starvation (Luethy 
and Holbrook, 1992; Tang et al., 2002; Oyadomari and Mori, 2004). Thus overexpression of 
DDIT3 will result in cell cycle arrest and apoptosis.  DDB2 is well known to function in 
genome nucleotide excision repair (Minig et al., 2009; Ennen et al., 2013; Roy et al., 2013; 
Zhao et al., 2014). DDB2 has recently been shown to play an important role in impeding 
tumour progression and tumour relapse. Upregulation of DDB2 prevents tumour progression 
and relapse (Han et al., 2014).  
The two different outcomes; surivial in MRC-5 and death in A549 are further supported by the 
upregulation of anti-angiogenic factor, ANGPT2 in A549 and pro-angiogenic factor, ANGPT1 
in MRC-5. Angiopoietin-2 (ANGPT2), is a natural antagonist for Tie2/TEK receptor that has 
been shown in vivo to disrupt angiogenesis (Maisonpierre et al., 1997). ANGPT1 a known anti-
angiogenic factor facilitates angiogenesis when it binds to its corresponding receptor, 
Tie2/TEK (Maisonpierre et al., 1997; Augustin et al., 2009).  
These results indicate that introduction of exogenous methyl pyruvate can protect normal 
MRC-5 cells from irinotecan-induced cell death by upregulating pro-angiogenic and survival 
pathways while inducing cell death in A549 cell by upregulating pro-apoptotic pathways.   
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Chapter 5: Conclusion and future prospects  
             
 
This is the first study to propose the potential molecular mechanism by which exogenous 
methyl pyruvate provides protection of normal cells exposed to a DNA damaging agent.  In the 
current study, exogenous methyl pyruvate was shown to have protective effects on irinotecan-
treated MRC-5 fibroblasts and enhanced apoptosis in similarly treated A549 and MDA-MB 
231 cells.  This study proposes that exogenous pyruvate has potential to protect normal cells 
during chemotherapy. It was also observed that exogenous methyl pyruvate protects irinotecan-
treated normal lung fibroblast cell line (MRC-5) probably by turning off the p53/p21 axis of 
the apoptotic pathways thereby inhibiting apoptosis. In contrast, the introduction of exogenous 
pyruvate kills the A549 cancer cells by enhancing the p53/p21 axis. Introduction of exogenous 
methyl pyruvate can also induce another p53-independent and caspase-independent cell death 
in MDA-MB 231 cells with mutant p53. Futherrmore, by microarray analysis it was observed 
that several genes are altered when normal and cancer cells are treated with irinotecan 
combined with exogenous methyl pyruvate. These alterations in specific genes promote the 
survival and growth of MRC-5 normal cells and death of A549 lung cancer cells. 
Future validation studies must be conducted, as the in vivo relevance of these findings has not 
been tested. Such studies may involve the use of nude mice to validate the role of exogenous 
methyl pyruvate on normal and cancer cells during chemotherapy.  
The knowledge provided by this study may provide an opportunity to protect patients 
undergoing chemotherapy from its toxic effects and increase the success rate of 
chemotherapeutic drugs. Economically, this drug combination therapy will also be cost 
effective as side-effects and relapse may be reduced, especially in developing countries such 
as South Africa. 
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Appendix A 
 
 
Figure A1. GeneRuler™ 1 kb plus DNA ladder 
 
Figure A2. New England Biolabs blue pre-stained protein standard broad range. 
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Figure A3: Analysis of flow cytometry sub G0/G1 cell distribution in A549 (A), MDA-MB 
231 (B), MRC-5 (C), and MRC-5 upon recovery (D). Experimental data was derived from 
three independent experiments and were considered statistically significant when the p-value 
was ≤ 0.05. When the p-value ≤ 0.001 (**) the difference was considered very statistically 
significant, when the p-value ≤ 0.05 (*) the difference was considered statistically significant 
and when the p-value ≥ 0.05 (ns) the difference was considered not to be statistically 
significant. The statistical analysis was done using the Graphpad software. The error bars 
reflect the standard error of the mean of biological replicates. The following symbols were used 
to represent each treatment; MP- methyl pyruvate, Ir- irinotecan, COT- cotreatment, and UN- 
untreated cells. 
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Figure A4 : Introduction of exogenous methyl pyruvate resulted in deregulation of apoptotic 
pathways in MRC-5 cells : Relative transcript (A - D) and protein (E - H) quantification 
measurements normalized by the expression of the house keeping genes, GAPDH and β-actin using 
MyImage AnalysisTM Software (Thermo Scientific) from one independent experiment in A549 lung 
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cancer cell line , MDA-MB 231 breast cancer cell line, MRC5 a non-tumorigenic cell line  and MRC5 
cells upon recovery from various treatments. 
 
Table A1: Cell cultures: All cell lines used in this study were purchased from ATTC 
(American type culture collection) Virginia, USA. 
Cell line Diagnosis Host p53 status 
 
MRC5 Normal Human  Wildtype (WT) 
MDA-MB 231 Breast cancer  Human   p53280R-K 
A549 Lung cancer  Human WT 
 
Table A2: Biological buffers and solutions 
Buffer/solution Composition 
 
1.5 M Tris-HClbuffer, pH 8.8 8.12 w/v % TRIS (hydroxymethyl) 
aminomethane 
0.5 M Tris-HCl  buffer, pH 6.8 0.36 w/v % TRIS (hydroxymethyl) 
aminomethane 
SDS Sample buffer  (5X) 62.5 mM Tris-HCl buffer (pH 6.8) 
10% Glycerol 
2% SDS 
5% β-Mercaptoethanol 
 
5% Running buffer, pH 8.3 25 mM Tris 
192 mM glycine 
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1% SDS 
Towbin buffer (pH 8.3) 25 mM Tris base 
192 mM glycine 
0.1%SDS  
20% (v/v) methanol on day of use. 
Phosphate buffered saline (PBS) 50X (pH 
7.3) 
1.4 M NaCl 
27 mM KCl 
101 mM Na2HPO4 
18 mM KH2PO4 
Citric Saline buffer 10X 1.35 M KCl 
0.15 M sodium azide 
TAE Buffer 10X  40 mM Tris 
20 mM Acetic acid  
1 mM EDTA 
 
Table A3:  Kits and laboratory equipment used  
Kits and equipment Suppliers 
 
RTCA DP ACEA XCELLigence analyzer, 
version 1.2 (2009) 
Roche (Biosciences Inc.) 
XCELLigence E-plate 16 (05469813001) Roche (Biosciences Inc.) 
BD Acurri TM C6 cytometer Biosciences 
RevertAid first strand cDNA synthesis kit 
(k1622) 
Thermo Scientific 
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ProtoScript first strand cDNA synthesis kit 
(E6300S; lot 0041411) 
BioLabs Inc. 
Taq 2x Master Mix Kit ( M0270L; lot 
0231412) 
BioLabs Inc. 
Polyscreen PVDF transfer membrane 
(NEF1002) 
Perkin Elmer Life Sciences Inc. 
GeneAmp 2400 thermal cycle PCR system 
(2400) 
Perkin Elmer  
Gel Doc XR+ imaging system (170-S170) Bio-Rad 
Nanodrop spectrophotometer Thermo Fischer Scientific USA 
Hoefer VE blotting module Amersham Biosience UK 
RT2 first cDNA strand kit (330401) QIAGEN 
DNase kit (AMPD1 – 1KT) Sigma 
Real-time light cycler machine LC-480 Roche 
INTERGA VIAFLO ASSIST Liquid 
handler (8-channel pipette 2-50 µl) (CH-
7205 Zizers) 
Interga Biosciences  
Low speed benchtop centrifuge LCM-3000 Grant Instruments 
RT2 ProfilerTM PCR array PAHS-O33ZF-
12 Human Cancer PathwayFinderTM 
(PAHS-033ZF-12) 
QIAGEN 
RT2 SYBR Green qPCR Mastermix  Kit 
(330500) 
QIAGEN 
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Table A4: Reagents and chemicals  
Name  Supplier and catalog 
number 
Chloroform (99 + %) Sigma (31k3695) 
Nuclease-free water  Qiagen (129117) 
Propan-2-ol Merk (1036573) 
Ethanol absolute ProLabo (VWR) 
(20820327) 
TRI reagent® Sigma (T9424) 
GeneRuler 1kb Plus DNA 
ladder (0.1 µg/µl) 
Thermo Scientific 
(SM1333) 
6X DNA loading dye Thermo Scientific (R0611) 
PageRulerTM  prestained 
protein ladder 
Thermo Scientific (26616) 
SuperBlock (PBS) blocking 
buffer 
Thermo Scientific (37580) 
Super Signal 
Chemiluminescent Substrate 
Kit (composition; 
Lumino/enhancer and stable 
peroxide buffer) 
Thermo Scientific (34087) 
RNase free-water QIAGEN (129117) 
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Table A5: Cell culturing reagents 
Media/ reagents  
 
Supplier and catalog number  
Dulbecco’s modified eagle’s medium Sigma (D6429) 
Fetal calf serum Highveld biological (NO.306) 
Penicillin/streptomycin antibiotics Sigma (074M 846V) 
Trypsin-EDTA solution Sigma (SLBK7106V) 
Irinotecan  Sigma (1347609 – 100MG) 
Methyl pyruvate  Sigma (P2881) 
 
Table A6: Oligonucleotides 
All primers were obtained from Inqaba Biotech except for the GAPDH primers which were 
supplied by Thermo Scientific.  
Primer 5'-3' sequence Tm 
(ºC) 
Catalog 
no./Barcode 
Reference 
GAPDH 
forward 
primer 
ACACTCAGACCCCCACCACA 58.0 00205654 (Erler et 
al., 2004) 
GAPDH 
reverse 
primer  
CATAGGCCCCTCCCCTCTT 58.0 00207076 (Erler et 
al., 2004) 
Bid 
forward 
primer 
GCTGTATAGCTGCTTCCAGTG 62.77 S3823 (Erler et 
al., 2004) 
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Bid 
reverse  
primer 
GCTATCTTCCAGCCTGTCTTCTC 64.55 S3824 (Erler et 
al., 2004) 
Bax 
forward 
primer 
CTGCAGAGGATGATTGCCG 62.32 S381F (Erler et 
al., 2004) 
Bax 
reverse  
primer 
TGCCACRCGGAAAAAGACCT 60.4 S3820 (Erler et 
al., 2004) 
Caspase-
3 
forward  
primer 
AGAACTGGACTGTGGCATTGAG 62.67 S3F31 (Tsang 
and 
Kwok, 
2008) 
Caspase-
3 
Reverse  
Primer  
GCTTGTCGGCATACTGTTTCA 60.61 S3F32 (Tsang 
and 
Kwok, 
2008) 
MDM2 
Forward  
primer 
ATCAGGCAGGGGAGAGTGAT 62.45 S3F33 (Moela, 
2013) 
MDM2 
Reverse  
Primer  
TCTACATACTGGGCAGGGC 62.45 S3F34 (Moela, 
2013) 
p21 
forward 
Primer  
ATGTCAGAACCGGCTGGGGA 60.61 S408A (Li and 
Wu, 2004) 
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p21 
reverse  
Primer  
GCCGTTTTCGACCCTGAGAG 62.57 S408B (Li and 
Wu, 2004) 
p53 
reverse 
primer 
CCCAGACGGAAAACCGTAGCTGCCT 71.1 S3822 (Teng et 
al., 2008) 
p53 
forward 
primer 
TCAGATCCTAGCGTCGAGCCCCCTCT 70.9 S3821 (Tseng et 
al., 2008) 
Caspase-
9  
reverse 
primer  
CATCTGGCTCGGGGTTACTGC 58.3 S3F88 (Chalfant 
et al., 
2002) 
Caspase-
9  
forward 
primer 
GCTCTTCTTTGTTCATCTCC 66.4 S3F87 (Chalfant 
et al., 
2002) 
 
Table A7: Antibodies used for Western blot analysis 
Primary antibody Secondary 
antibody 
Catalogue number Supplier 
 
pAB anti-RBBP6 
rabbit polyclonal 
(1:500) 
Anti-rabbit IgG-
peroxidase raised in 
goat (1:5000) 
NBPI-49535 and 
A8919 
Novus Biologicals 
and Sigma 
Anti-Cytochrome c 
goat IgG polyclonal 
(1:1000) 
Anti-goat IgG- 
peroxidase raised in 
rabbit  (1:5000) 
Sc-7159 and A-0545 Santa Cruz and 
Sigma 
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Anti-actin mouse 
IgG monoclonal 
(1:500) 
Anti-mouse IgG-
peroxidase goat 
(1:1000) 
Sc-8432 and Sc-
2005 
Santa Cruz  
Ab28 anti-p53 
mouse monoclonal 
(1:500) 
Anti-mouse IgG-
peroxidase goat 
(1:5000) 
PAb 1801 And Sc-
2005 
Abcam and Santa 
Cruz 
 
Table A8: Web address for the various Bioinformatics tools used in this study 
Tool Web addresses  
 
GeneGlobe (QIAGEN 
software) 
www.qiagen.com/za/shop/genes-and-pathways/data-analysis-
center-overview-page/rt2-profiler-pcr-arrays-data-
analysiscenter/?Instrument=Roche_480_96&format=F&catno 
=PAHS-033Z 
PANTHER http://www.pantherd.org/ 
REACTOME http://www.reactome.org/ 
GeneMANIA  http://genemania.org/ 
 
Table A9: Statistical analysis (means ± SD) of the cell cycle phases for untreated and treated cells   
Cell lines Cell 
cycle 
phases 
% of cells at cell cycle phase  
UN 4 IR 24 
IR 
48 
IR 
4 
MP 
24 
MP 
48 
MP 
 4 
COT 
24 
COT 
48 
COT 
 
 
RMG1 
Sub 
G0/G1 
3.3 ± 
0.2  
12.2 
± 0.2 
13.2 
± 0.2 
26.0 
± 0.1 
1.3 ± 
0.1 
6.5 ± 
0.1 
19.3 
± 0.2 
5.1 ± 
0.1 
5.2 ± 
0.1 
51.2 
± 0.2 
G0/G1 83.4 
± 0.2  
71.0 
± 0.1 
79.8 
± 0.1 
33.3 
± 0.3 
2.3 ± 
0.2  
88.3 
± 0.1 
77.5 
± 0.1 
75.2 
± 0.2 
9.1 ± 
0.2 
46.8 
± 0.1  
S 12.5 
± 0.1 
12.0 
± 0.1 
 6.1 
± 0.2  
38.0 
± 0.2 
88.2 
± 0.2 
4.3 ± 
0.1 
4.3 ± 
0.1 
17.3 
± 0.2 
40.0 
± 0.1 
2.1 ± 
0.2 
G2/M  0.8 ± 
0.1 
8.8 ± 
0.3 
1.0 ± 
0.3 
0.3 ± 
0.1 
4.8 ± 
0.2  
1.0 ± 
0.2 
2.4 ± 
0.1 
2.3 ± 
0.2 
46.0 
± 0.2 
0.2 ± 
0.1 
 
 
A549 
Sub 
G0/G1 
0.5 ± 
0.1 
12.5 
± 1.0 
69.2 
± 0.5  
37.3 
± 1.0  
13.5 
± 2.0 
70.2 
± 1.5 
36.5 
± 0.3 
24.1 
± 0.1 
52.7 
± 0.3 
90.1 
± 0.1 
G0/G1 90.7 
± 0.1 
79.1 
± 1.0 
29.1 
± 1.0 
56.4 
± 1.0 
77.1 
± 3.0 
28.6 
± 1.5 
57.1 
± 0.3 
69.5 
± 0.1 
44.4 
± 0.3 
9.2 ± 
0.2 
S 5.2 ± 
0.2 
6.9 ± 
0.2  
1.9 ± 
0.2  
4.0 ± 
0.1 
7.0 ± 
0.5 
1.9 ± 
0.2 
4.0 ± 
0.1 
5.5 ± 
0.2  
2.7 ± 
0.2 
1.0 ± 
0.1 
G2/M 3.7 ± 
0.2 
2.5 ± 
0.2 
0.3 ± 
0.2  
2.8 ± 
0.1 
2.2 ± 
0.5 
0.3 ± 
0.2 
2.9 ± 
0.1 
1.2 ± 
0.2 
0.3 ± 
0.2 
0.1 ± 
0.1 
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MDA-MB 
231 
Sub 
G0/G1 
3.6 ± 
0.1 
17.1 
± 1.0 
41.5 
± 0.1  
36.9 
± 0.1  
16.3 
± 0.2 
41.6 
± 0.2 
36.9 
± 0.1 
4.4 ± 
0.2 
7.1 ± 
0.1 
35.7 
± 0.1 
G0/G1 70.3 
± 0.1 
44.9 
± 1.0   
54.8 
± 0.2  
51.9 
± 0.1 
45.9 
± 0.1 
54.3 
± 0.3  
51.9 
± 0.1 
51.1 
± 0.2 
79.7 
± 0.1 
34.8 
±0.1 
S 16.2 
± 0.2 
29.7 
± 0.1 
2.8 ± 
1.0 
7.5 ± 
0.1 
30.1 
± 1.0  
2.4 ± 
0.1 
7.5 ± 
0.1 
34.1 
± 0.1 
10.7 
± 0.1 
20.1 
± 0.1 
G2/M 9.9 ± 
0.2 
15.3 
± 0.1 
1.0 ± 
1.0  
3.9 ± 
0.1 
14.9 
± 1.0 
1.4 ± 
0.1  
3.9 ± 
0.1 
10.5 
± 0.1 
2.6 ± 
0.2 
19.4 
± 0.1 
 
 
MRC-5 
Sub 
G0/G1 
1.2 ± 
0.2 
6.6 ± 
0.3 
3.9 ± 
0.3  
6.5 ± 
0.3  
6.6 ± 
0.3  
3.7 ± 
0.1  
6.3 ± 
0.1 
4.2 
±0. 2 
4.2 ± 
0.2 
6.2 ± 
0.2 
G0/G1 91.6 
± 2.0 
80.1 
± 0.1  
80.1 
± 0.3  
74.9 
± 0.3 
82.7 
± 2.5 
80.3 
± 0.1  
75.1 
± 0.1 
82.5 
± 0.2 
82.5 
± 0.2 
88.1 
± 0.3 
S 8.6 ± 
0.1 
9.9 ± 
0.1  
13.4 
± 0.2 
11.2 
± 0.1 
10.0 
± 0.3 
13.3 
± 0.2  
11.5 
± 0.4 
12.5 
± 0.2 
11.5 
± 1.5 
5.5 ± 
0.2 
G2/M 0.4 ± 
0.1 
0.7 ± 
0.2  
2.8 ± 
0.2 
2.6 ± 
0.1  
0.6 ± 
0.3 
2.8 ± 
0.2  
2.2 ± 
0.4  
0.7 ± 
0.2 
0.5 ± 
0.2 
 0.4 ± 
0.2 
 
MRC-5 
(Recovery) 
Sub 
G0/G1 
1.1 ± 
0.1 
5.5 ± 
0.3  
6.1 ± 
0.1 
5.9 ± 
0.3  
5.3 ± 
0.1  
6.3 ± 
0.3  
5.9 ± 
0.2 
1.1 ± 
0.1 
9.3 ± 
0.2 
1.3 ± 
0.1 
G0/G1 94.1 
± 0.1 
85.0 
± 0.3 
76.6 
± 0.2 
65.0 
± 0.3 
85.1 
± 0.1  
76.1 
± 0.3  
65.0 
± 0.2 
84.3 
± 0.1 
80.9 
± 0.2 
56.4 
± 0.1 
S 4.3 ± 
0.1 
9.0 ± 
0.3 
15.7 
± 0.3 
26.0 
± 0.2 
8.9 ± 
0.2  
15.7 
± 0.3 
26.0 
± 0.2 
13.9 
± 0.1 
9.2 ± 
0.2 
30.6 
± 0.3 
G2/M 0.6 ± 
0.1  
0.6 ± 
0.3 
1.7 ± 
1.5 
3.3 ± 
0.2 
0.7 ± 
0.2 
3.0 ± 
0.3  
3.2 ± 
0.2 
0.7 ± 
0.1 
0.7 ± 
0.2 
11.7 
± 0.3 
 
UN – Untreated IR – Irinotecan  MP – Methyl pyruvate COT – Cotreatment  
 
 
 
 
 
 
 
 
 
 
 
 
B. Monchusi: PhD Thesis  
137 
 
Appendix B 
 
A. A549 upregulated pathways/processes  
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B. A549 downregulated pathways/processes  
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C. MRC-5 upregulated pathways/processes 
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 Figure B2: Pathway diagrams constructed using the REACTOME pathway analysis. 
Pathways were enriched when a significant number of the query list genes were part of a 
particular pathway against the overall pathway genes. The dark green colour represents genes 
with upregulated expression levels while the bright yellow colour represents downregulated 
genes. The purple and orange colours indicate downstream molecules which were enriched, 
and the values in the red circles at the top left corner indicates the number of downstream 
interacting molecules. Each pathway was considered statistically enriched when the p < 0.05.  
In A549 lung cancer cells, the combined treatment upregulated genes involved in (a1-a2); 
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regulation of necrosis ( p = 0.56E-5), intrinsic programmed cell death (p = 2.22E-2), packaging 
of telomere ends ( p = 1.9E-2), dual inclusion GC:NER ( p = 2 E-3), recruitment of POLB to 
AP site: abasic sugar-phosphate removal ( p = 1.44E-2), cellular response to hypoxia ( p = 
1.19E-1), signalling by VEGF (p = 6.26E-1), and telomere stress induced senescence ( p = 
4.46E-2). Furthermore, in A549 lung cancer cells, the combined treatment downregulated 
genes involved in (b1-b2); DNA strand elongation: unwinding of DNA (p = 7.53E-6), 
activation of pre-replicative complex (p = 6.66E-5), mitotic G0/G1/S phase (p =6.21E-4), 
signalling by VEGF (p = 3.31E-1), cellular response to oxidative stress (p = 5.86E-4), 
detoxification of ROS (p = 1.44E-3), and metabolic genes regulated by TP53 (p = 2.35E-2). In 
MRC-5 normal lung fibroblast cells, the combined treatment upregulated genes involved in 
(c1-c2); signalling by VEGF (p = 3.02E-4), Tie2 signalling ( p =3.38E-2), regulation and 
transport of IGF by IGFBP5 (p = 3.61E-2), Dissolution of fibrin clot (fibrinolysis) (p = 3.42E-
2),cellular response to hypoxia ( p = 1.32E-2), POU5F1 (OCT4), S0x2, NANOG repress genes 
related to differentiation ( p = 1.72E-2), and heme degradation (p = 2.02E-2). The REACTOME 
key diagram below gives detail description of the icons used. 
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Table B1:  17 unique genes upregulated in A549   
Gene Full name Function Reference 
 
CASP7 Caspase-7 Induce apoptosis by 
cleavage of a large 
set of substrates  
Lamkanfi and 
Kanneganti, 2010 
CFLAR CASP8 and 
FADD-like 
apoptosis 
regulator  
 
Anti-apoptotic 
factors  that inhibits 
the extrinsic 
pathway by binding 
to tumour necrosis 
factor receptors 
(TNF-R) 
Wajant et al., 2005; 
Lin et al., 2000; 
Wajant, 2004 
BIRC3 Baculoviral IAP 
Repeat Containing 3 
DDIT3 DNA damage 
inducible transcript 
3' (Formerly CHOP) 
key regulator in 
stress response (ER 
stress, DNA 
damage, hypoxia, 
and starvation) 
Luethy and 
Holbrook, 1992; 
Oyadomari and 
Mori, 2004; Tang et 
al., 2002 
PPP1R15A phosphoprotein 
phosphatase 
regulatory subunit 
15A also 
GADD34 
Induce growth arrest 
upon detection of 
damaged DNA 
Zhan et al., 1994; 
Arumugam et al., 
2011 
POLB DNA polymerase 
beta 
DNA repair 
polymerase involved 
in base-excision 
repair, DNA 
replication and trans 
lesion synthesis 
Masaoka et al., 
2009; Beard and 
Wilson, 2006 
DDB2 Damage specific 
DNA protein 2 
Function in genome 
nucleotide excision 
repair by acting as a 
transcription 
regulator 
Minig et al., 2009; 
Ennen et al., 2013; 
Zhao et al., 2014; 
Roy et al., 2013 
ERCC5 Excision repair 
cross-species 
complementation5 
Important protein the 
two incision steps in 
nucleotide-excision 
repair 
Godwa et al., 2007 
ACL4 Acyl-CoA 
synthetase long-
chain family member 
4 
Catalyzes the ATP-
dependent 
thioesterification of 
fatty acids to 
coenzyme A (CoA) 
Watkins et al., 2007 
BMI Polycomb group 
gene 
Positively regulate  
proliferation and 
negatively regulate 
cellular senescence 
and differentiation  
Sparman and Van 
Lohuizen, 2006 
TNKS2 Tankyrase-2 Act as a positive 
regulator of telomere 
length 
Smith and de Lange, 
2000 
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TINF2 TRF1 interacting 
nuclear factor 
2 
Negatively 
regulating telomere 
length 
Kim et al., 1999 
TERF2IP Telomeric repeat 
binding factor 
1 
Protects human 
telomeres from end-
to-end fusion 
van Steensel et al., 
1998 
VEGFC Vascular endothelial 
growth 
factor-FC 
Bind to lymphocyte 
vessel endothelial 
cells and stimulate 
lymphangiogenesis 
Tammela and 
Alitalo, 2010 
ANGPT2 Angiopoietin-2 Anti-angiogenesis 
factor 
Asahara et al., 1998 
ARNT Aryl 
hydrocarbon nuclear 
translocator 
Control of glucose 
metabolism  
Zelzer et al., 1998 
SNAI2 Snail 2 Regulate epithelial-
mesenchymal 
transition (EMT). It 
also influences 
metastasis 
Baygi et al., 2010; 
Chaffer and 
Weinberg, 2011 
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Table B2: 18 unique genes downregulated in A549 
Gene  Full name Function Reference 
FLT1/ VEGFR1 Vascular endothelial 
growth factor 
receptor 1 
Facilitate 
angiogenesis by 
increasing vascular 
endothelial cell 
growth and 
proliferation 
Park et al., 1994; 
Hiratsuka et al., 
2002 
ANGPT1 Angiopoietin-1 Mediator of VEGF-
independent pro-
angiogenic 
signalling pathway. 
Through its 
interaction with TIE2 
receptor, can 
activate the 
PI3K/AKT pathway 
Shim et al., 2007; 
Papapetropoulos et 
al., 2000 
SERPINF1 Serpin peptidase 
inhibitor clade F, 
member 1 
Inhibits 
angiogenesis  
Steele et al., 1993; 
Becerra et al., 1995 
FOXC2 Forkhead box C2 Transcription factor 
that induce 
Epithelial-to-
mesenchymal 
transition (EMT), 
which is essential for 
development of 
embryonic 
mesoderm 
Yilmaz and 
Lehembre, 2007 
HMOX1 Heme_oxygenase 1 Catalyzes the 
degradation of heme 
to carbon monoxide, 
free iron and 
biliverdin which is 
further converted to 
bilirubin 
Ryter et al., 2006 
DKC1 Dyskeratosis 
congenital 1, 
dyskerin 
Necessary for the 
biogenesis of the 
RNA component of 
telomerase (hTR) 
and regulates a 
number of anti-
apoptotic proteins 
Chang et al., 2002; 
Yoon et al., 2006 
ETS2 Transcription factor ( 
ETS protein 
family) 
ETS2 is involved in 
cell cycle control, its 
downstream target 
genes include; Bcl-
2, cyclin D1, and 
Bcl-XL 
Carbone et al., 
2004; 
Sementchenko et 
al., 1998 
CCND3 Cyclin D3 Involved in G0/G1 to 
S phase cell cycle 
progression 
Walker and Assoian, 
2005 
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CDC20 Cell division cycle 
20 
Plays a key role in 
activating the 
anaphase promoting 
complex (APC/C), 
leading to mitotic 
progression 
Hoeller et al., 2006 
AURKA Aurora kinase 1 Critical for bipolar-
spindle assembly, 
regulation of cell 
migration and 
adhesion, and 
recently reported to 
regulate stem cell 
self-renewal, 
reprogramming and 
differentiation 
Tsai et al., 2003; Do 
et al., 2013; Li and 
Rana, 2012 
STMN1 Stathmin 1 The microtubule-
destabilizing protein, 
is essential during 
mitosis, to influence 
cell cycle 
progression 
Rana et al., 2008; 
Belletti and 
Baldassarre, 2011 
MKI67 Antigen identified by 
monoclonal 
antibody ki-67 
Associated with 
cellular proliferation 
Gerdes et al., 1983 
SKP2 S-phase kinase-
associated protein 
2, E3 ubiquitin 
protein ligase 
Component of the 
SKP1-Cullin1-F-box 
(SCF) E3 ligase 
complex that is 
involved in cell cycle 
progression 
Bashir and Pagano, 
2004; Frescas and 
Pagano, 2008 
PINX PIN1/TERF1 
interacting, 
telomerase inhibitor 
1 
Important in 
maintenance of 
genetic stability, 
helicase activation 
and ribosome 
biogenesis 
Arndt and 
Mackenzie, 2016 
MCM2 Minichromosome 
maintenance 
complex component 
2 
Crucial for DNA 
replication and cell 
cycle initiation 
Kearsey and Labib, 
1998; Torres-
Rendon et al., 2009 
G6PD Glucose-6-
phosphate 
dehydrogenase 
An enzyme forming 
part of the glycolysis 
pathway is involved 
in the first reaction in 
the pentose-
phosphate pathway 
Cappellini and 
Fiorelli, 2008 
COX5A C y t o c h rome c 
oxidase subunit Va 
Encodes the Va 
subunit of the 
human 
mitochondrial 
respiratory chain 
enzyme, that is 
essential for 
Chen et al., 2012 
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regulation and 
assembly of the 
mitochondrial 
electron transport 
chain 
SOD1 Superoxide 
dismutase 1 
Catalyze the 
conversion of 
intracellular 
superoxide to 
hydrogen peroxide 
(H2O2). 
Overexpression of 
SOD1 promotes 
lung cancer cell 
growth and reduce 
apoptosis. 
Juarez et al., 2008; 
Somwar et al., 2011 
  
Table B3: 13 unique genes upregulated in MRC-5 
Gene Full name Function Reference  
ANGPT1 Angiopoietin-1 
 
 
Mediate cell-cell 
adhesion and cell 
survival. It’s a 
ligand of the 
receptor,  
TEK/Tie2. 
Together, they 
control vascular 
morphogenesis 
and homeostasis. 
Augustin et al., 
2009; 
Maisonpierre et 
al., 1997; 
Fukuhara et al., 
2008; Saharinen 
et al., 2008 
TEK/ Tie2 TEK tyrosine kinase, 
endothelial 
SERPINF1 Serine protease inhibitor F1 Angiogenesis  
 
Steele et al., 
1993; Becerra et 
al., 1995 
SERPINB2 Serine Protease inhibitor 2 
(Also - Plasminogen Activator 
Inhibitor-2) 
Important during 
cell 
differentiation, 
tissue growth and 
regeneration. 
Croucher et al., 
2008 
KDR Vascular Endothelial Growth 
Receptor  
Receptors that 
binds to VEGF-A 
ligand, thereby 
facilitating 
angiogenesis, 
vascular 
permeability, cell 
migration, gene 
expression and 
regulation of 
endothelial 
function 
Shibuya and 
Claesson-
Welsh, 2006; 
Lee et al., 2007 
PGF Placenta growth factor ligand 
(vascular endothelial growth 
factor-related protein) 
Bind and activate 
VEGFR-1 
receptor thereby 
Carmeliet et al., 
2001 
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contributing to 
angiogenesis 
SOX10 SRY-box 10 Nuclear 
transcription 
factor involved in 
neural crest 
development and 
differentiation of 
melanocytic and 
schwannian 
lineage 
Mollaaghababa 
and Pavan, 
2003 
GSC Goosecoid Involved in 
mesoderm 
formation in 
Drosophila and 
neural crest 
development in 
vertebrates 
during 
embryogenesis 
Thiery and 
Sleeman, 2006 
IGFBP5 Insulin growth factor-binding 
protein 5 
Essential during 
development of 
several key cell 
lineages such as 
myoblasts and 
neural cells 
James et al., 
1996; Cheng et 
al., 1999 
EPO Erythropoietin/thrombopoietin Essential in the 
regulation of red 
blood cell mass, 
participating in 
negative 
feedback control 
from a renal 
oxygen sensor to 
the erythroid 
system 
Lacombe et al., 
1988 
HMOX1 Heme_oxygenase 1 Catalyzes the 
degradation of 
heme to carbon 
monoxide, free 
iron and biliverdin 
which is further 
converted to 
bilirubin 
Ryter et al., 
2006 
GADD45G Growth arrest DNA-damage-
inducible protein 45 
Act as stress 
sensors and 
tumour 
suppressors 
during cellular 
genotoxic and 
non-genotoxic 
stress response 
Garcia et al., 
2005 
FASLG Fas ligand, also known as 
TNFSF6/CD95L 
Induces extrinsic 
apoptosis upon 
Wajant et al., 
2003 
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binding to its 
corresponding 
death-inducing 
receptor 
 
Table B4: 7 common genes upregulated in A549 and MRC-5  
Gene Full name Function Reference 
KRT14 Keratin 14 Part of the 
intermediate 
filament -forming 
proteins of epithelial 
cells. Crucial for 
survival. Participate 
in both natural 
cycling and repair of 
injury in normal cells 
Moll et al., 2008; 
Lloyd et al., 1995; 
Papafotiou et al., 
2016 
SNAIL1 Snail 1 
Snail 3 
Important in the 
induction of the 
epithelial to 
mesenchymal 
transition (EMT) 
converting epithelial 
cells into 
mesenchymal cells. 
SNAIL signalling 
induced a glycolytic 
switch 
Barrallo-Gimeno and 
Nieto, 2005; Lee et 
al., 2012 
SNAIL3 
CCND2 Cyclin D2 Promotes transition 
through the G1 
phase of the cell 
cycle 
Quelle et al., 1993 
CA9 Carbonic anhydrase 
IX 
Involved in pH 
regulation of the 
extracellular 
microenvironment 
during hypoxia and 
is regulated by HIF-
1α 
Neri and Supuran, 
2011; Kaluz et al., 
2009;  
TEP1 Telomerase-
associated protein 1 
A putative regulator 
domain and is 
associated with 
telomerase activity 
Nakamura et al., 
1997; Nakayama et 
al., 1997 
TBX2 T-box 2 Acts mainly as a 
transcriptional 
repressor regulating 
cell migration and 
morphogenesis 
during 
embryogenesis 
Carreira et al., 1998; 
Suzuki et al., 2004 
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Table B5: Upregulated pathways after the drug combination in A549 and MRC-5 cells using 
GeneMANIA analysis  
Molecular Functions                     q-values of upregulated pathways 
A549 MRC-5 
telomere maintenance via 
telomerase 
3.2e-12 -- 
 
intrinsic apoptotic signalling 
pathway 
2.9e-05 -- 
 
vascular endothelial growth 
factor receptor signalling 
pathway 
0.13 -- 
positive regulation of 
endothelial cell proliferation 
0.022 -- 
programmed necrotic cell 
death 
0.0022 -- 
positive regulation of 
protein ubiquitination 
0.023 -- 
nucleotide excision repair 
DNA damage removal 
0.0027 -- 
regulation of endothelial cell 
proliferation 
0.027 -- 
metabolism proteins 0.068 -- 
 
Angiogenesis -- 
 
1.3e-08 
 
cellular response to hypoxia -- 0.0017 
 
regulation of insulin-like 
growth factor receptor 
signalling pathway 
-- 0.030 
positive regulation of cell 
adhesion 
-- 0.0037 
regulation of DNA 
replication 
-- 0.058 
regulation of extrinsic 
apoptotic signalling pathway 
-- 0.067 
 
 
Table B6: Downregulated pathways after the drug combination in A549 cells using 
GeneMANIA analysis  
Molecular Functions                     q-values of downregulated pathways 
A549 MRC-5 
Angiogenesis 0.021 -- 
 
DNA polymerase activity 0.021 -- 
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Mitosis 
 
0.022 -- 
Myeloid cell homeostasis 
 
0.099 -- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
